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ABSTRACT 
Recent studies indicate that endogenously ligand-activated Aryl 
Hydrocarbon Receptor (AHR) plays an important role in normal and pathological 
processes, including the induction and progression of breast cancer. As the 
known number of AHR-mediated processes grows, so too does the importance 
of identifying endogenous AHR ligands that influence breast cancer progression. 
The following studies focus on two tryptophan metabolism pathway branches, the 
kynurenine (KYN) branch and the indoxyl sulfate (IS) branch, to determine if ER-
/PR-/HER2- breast cancer cells can produce, or are exposed to, AHR ligands 
from these branches, how these ligands affect cell migration and, if produced, 
how their production is controlled. It is hypothesized that: 1) malignant cells 
produce, or derive from their microenvironment, AHR ligands through the KYN 
  vii 
and/or IS pathways, 2) these metabolites drive AHR-dependent breast cancer 
migration, 3) environmental AHR ligands mimic the effects of endogenous 
ligands, 4) rate-limiting kynurenine pathway enzymes are responsible for 
endogenous AHR ligand production and their downstream effects, and 5) the 
AHR controls expression of a rate-limiting kynurenine pathway enzyme(s) in a 
positive feedback loop. ER-/PR-/HER2- mammary epithelial cells were assayed 
for production of AHR-activating tryptophan metabolites and for the kynurenine 
pathway enzymes tryptophan 2,3-dioxygenase (TDO) and indolamine 2,3-
dioxygenase (IDO). The relationship between kynurenine and IS pathways, AHR 
activity, cell migration, and aldehyde dehydrogenase 1 (ALDH1), a cancer stem 
cell marker associated with poor prognosis, was investigated using tryptophan 
metabolites, enzyme-specific gene knockdown or over-expression, qPCR, cell 
migration assays and ALDH1 activity assay. ER-/PR-/HER2- tumor cells produce 
KYN and its downstream metabolite xanthurenic acid (XA), at levels sufficient to 
activate the AHR. KYN, XA, and IS significantly accelerate migration in an AHR-
dependent fashion, and at physiological doses, while environmental AHR ligands 
2,3,7,8-tetrachlorodibenzodioxin (TCDD) and benzo[a]pyrene (B[a]P) mimic this 
effect. IS induces ALDH1 activity. AHR knockdown or inhibition significantly 
reduces Tdo2 expression. Finally, gene expression dataset analyses reveal high 
Tdo2 levels in primary breast tumors, with the highest levels in ER-/PR-/Her2- and 
stage 4 tumors. These studies identify three tryptophan-derived AHR ligands that 
contribute to breast cancer progression and demonstrate a positive feedback 
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loop, where AHR activity up-regulates Tdo2, which drives endogenous AHR 
ligand production.  
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INTRODUCTION 
1. Breast cancer overview 
1.1 Breast cancer incidence and known risk factors 
Breast cancer is the most common cancer diagnosed in women worldwide 
(Pizot et al. 2016) and accounts for 29% of all cancers diagnosed and 16% of all 
cancer deaths in US women (Siegel et al. 2014).  It is estimated that in 2015 
alone there will be approximately 231,840 new breast cancer cases and 
approximately 40,290 women will die of the disease (NCI 2016). A recent study, 
using data from the National Cancer Institute and the U.S. Census Bureau, 
forecasted that breast cancer rates in women will grow from 283,000 cases in 
2011 to 441,000 in 2030, a more than 50 percent increase (NCI, 2016).  These 
trends highlight the importance of identifying pathways for prevention, early 
detection and finding a cure for breast cancer.  
Known factors affecting breast cancer risk include genetic predisposition 
(approximately 10% of cases), hormone exposure (Key et al. 2002; Brody and 
Rudel 2003; Missmer et al. 2004), and several modifiable life style factors. A 
well-known example of a genetic mutation that predisposes breast cancer is 
BRCA1 mutation. Lifetime exposure to endogenous hormones may be influenced 
by age of menarche, age of first childbirth and age of menopause, all of which 
have been shown to affect breast cancer risk (Brody and Rudel 2003).  An 
example of exogenous hormone exposure is hormone replacement therapy, a 
known risk factor for breast cancer in post-menopausal women (Beral and Million 
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Women Study 2003). Known modifiable lifestyle risk factors for breast cancer 
include alcohol consumption, sedentary lifestyle, and obesity (Veronesi et al. 
2005). The increasing prevalence of eating a western diet and a sedentary life 
style, which are likely to increase the enhance the effects of known risk factors 
such as obesity, late life-child bearing and aging, will likely continue contributing 
to a rise in worldwide breast cancer burden.  Identification of and research on 
modifiable factors for reduction of breast cancer risk should therefore be a public 
health priority.  
1.2. Environment as a source of breast cancer risk 
Established risk factors, including genetics, account for only about 40 – 
50% of breast cancer cases (Madigan et al. 1995), indicating that additional 
environmental risk factors are major contributors to breast cancer risk. There has 
been a marked increase in breast cancer incidence in the past 50 years (Ursin et 
al. 1994; Althuis et al. 2005). Although mammography screening may have 
contributed to rise in breast cancer diagnosis in the 1980, neither mammography 
nor any known risk factors can explain an increase in incidence prior to 1980, or 
the increased incidence in developing countries where screening rates are low 
(Ursin et al. 1994; Soto and Sonnenschein 2015).  Migration of women from low-
risk to higher-risk countries, and vice-versa, leads to acquisition of the risk in the 
destination country, highlighting the potential role of modifiable environmental 
factors (Brody et al. 2007).  
An increase in breast cancer risk in the past 50 years is historically 
  
3 
associated with an introduction of a plethora of industrial process byproducts and 
new synthetic chemicals into the environment (Soto and Sonnenschein 2010).  
Compounds produced by industrial processes, including components of gasoline, 
aromatic amino/nitrino compounds, dyes, epoxides, products of combustion, 
industrial solvents and pesticides, have been identified as mammary 
carcinogens, and in some cases as genotoxic (Brody et al. 2007). Based on 
epidemiologic observations and animal studies, it has been hypothesized that 
industrial pollution contributes significantly to breast cancer risk.  In recognition of 
this, a 2010 report authored by “the President’s Cancer Panel” stated, “…the true 
burden of environmentally-induced cancers has been grossly underestimated” 
(Leffall and Kripke 2009).  
1.3. Breast cancer biology. 
Breast cancer research in vitro usually employs cells that have been 
obtained from breast cancer patients, immortalized and cultured in two or three-
dimensional cultures. Physiologically, however, the structure of mammary glands 
where breast cancer may develop is considerably more complicated than the cell 
culture used to model it. Components of human breast include the breast 
parenchyma, which contains the internal structures of the breast, superficial 
fascia, which envelops breast parenchyma, and skin.  Breast parenchyma is 
composed of 15–20 lobes connected by ducts and surrounded by fibrous tissue 
and supporting fat (Pizot et al. 2016) Each of the lobes is composed of ducts, 
which open into lobules at their terminal end. The ducts are lined with one to two 
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layers of ductal epithelium, while the lobules, also referred to as terminal ducts, 
acini or milk-producing glands, are lined with milk-producing epithelium (Aydiner 
2016). The inner epithelia of ductal and lobular structures are enveloped by a 
cell-deposited basement membrane.  
Breast cancer prognosis worsens dramatically as the disease progresses 
towards metastasis.  Diagnostically breast cancers are classified according to 
their stage of progression, as will be discussed in further detail in the next 
section. On a cellular level, the first step of progression towards metastasis is 
tumor invasion, which occurs when tumor cells beak through the basement 
membrane and move into the surrounding tissue. While normal epithelial cells 
are cuboidal and tightly connected to each other and the extracellular matrix 
(ECM) by multiple cell adhesions (Thiery and Sleeman 2006), invasive cells 
acquire spindle-like morphology, weaker focal adhesions, increased motility, and 
an ability to digest, and move through, the ECM (Thiery and Sleeman 2006). 
These changes are accompanied by changes reminiscent of epithelial-to-
mesenchymal (EMT) transition of embryonic development, such as up regulation 
of master EMT regulators, Slug, Snail and Twist (J. Yang et al. 2004; Thiery and 
Sleeman 2006), loss of the trans-membrane cell-cell adhesion protein E-cadherin 
(Steeg 2006), an increase in invasion-associated protein N-cadherin (Steeg 
2006), and an increase in expression of matrix-degrading metalloproteinases 
(MMPs) (Kohrmann et al. 2009).   For this project, cell motility, a key step in 
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tumor cell invasion, was used as the prototypic characteristic of breast cancer 
cell line invasiveness.  
1.3. Breast cancer classification  
Breast cancer is a heterogeneous disease with a wide range of molecular, 
pathologic and clinical characteristics. At diagnosis, breast cancers are classified 
according to histopathological sub-types and stage of progression. Tumors 
typically originate in the epithelial cells of the parenchyma of the breast and are 
classified as invasive or non-invasive based on whether the tumor has 
penetrated (invaded) the surrounding basement membrane. The majority of 
tumors are termed invasive ductal carcinomas non-otherwise-specified, due to 
their invasive nature and a lack of histological resemblance to any particular 
subtype.  The rest of the tumors are classified as lobular, tubular, medullary or 
metaplastic (Leffall and Kripke 2009). 
 Stage classification involves the level of clinical progression of breast 
tumors, based on size and metastasis. Metastatic spread occurs when tumor 
cells gain access to the lymphatic and vascular systems (2016). Tumors that are 
two centimeters or less and have not metastasized are Stage I tumors.  Stages II 
and III are more advanced, may be larger than two centimeters and involve 
metastasis to nearby lymph nodes. Stage IV tumors involve metastasis to distant 
organs (I.O. 2003). Prognosis for the disease becomes progressively worse as 
the stage of cancer becomes more advanced.  
Molecular categorization involving receptor status is currently used for 
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prognostic purposes, and for treatment selection or development. Seventy to 
80% of cancers are positive for the estrogen receptor (ER) and the progesterone 
receptor (PR). These cancers may be sensitive to hormone-based therapeutics. 
Fifteen to 20% of cancers overexpress epidermal growth factor receptor (HER2) 
protein and may be responsive to treatment with anti-HER2 antibody (Dawson et 
al. 2013). The remaining 10–15%, which do not have the presence of these three 
receptors, are classified as triple negative breast cancers (TNBC) (Dawson et al. 
2013). TNBC has a poorer prognosis than other types of breast cancer in terms 
of distant metastasis, relapse and death (Amos et al. 2012; Shim et al. 2014).  
Moreover, TNBCs are not responsive to hormone or HER2-based treatments.  
Despite the importance of current classifications for prognostic and 
treatment purposes, large variations in treatment response and disease 
progression within each subgroup still present great challenges for successful 
cancer treatment. Consequently, extensive effort is directed towards identifying 
and dissecting molecular mechanisms that drive breast cancer progression, with 
the goal of identifying new prognostic markers and therapeutic targets.  This 
study focuses on the role of one such promising molecular mechanism involving 
Aryl Hydrocarbon Receptor (AHR) signaling, in progression of TNBC, for which 
there is a lack of targeted treatment options (Ovcaricek et al. 2011). 
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2. The Aryl Hydrocarbon Receptor (AHR) 
2.1. AHR structure 
The AHR is a member of the basic Helix-Loop-Helix PER/aryl hydrocarbon 
receptor nuclear translocator (ARNT)/single minded (SIM) (bHLH-PAS) protein 
family (Kewley et al. 2004). bHLH-PAS proteins are ubiquitous transcription 
factors critical for regulation of physiological and developmental processes, 
including xenobiotic metabolism, hypoglycemia, low oxygen tension, neural 
development and circadian rhythm. Structurally, bHLH/PAS proteins consist of 
two adjacent 130 amino-acid repeats PAS A and PAS B and the bHLH domain at 
the N-terminal (Kewley et al. 2004).  The most extensively studied mechanism for 
bHLH/PAS protein signaling involves heterodimerization with another member of 
the family, and binding of the dimer to the DNA to modify gene transcription.  
The bHLH domain of the AHR contains the DNA-binding region, 
dimerization region, nuclear localization signal (NLS) (Ikuta et al. 1998) and 
nuclear export sequence (NES). The PAS A domain of the AHR is adjacent to 
the C-terminal of bHLH domain and contains a part of the dimerization domain, 
while PAS B domain is located next to the PAS A domain and contains the 
ligand-binding region. Ligand binding is the key initiating step in AHR signaling.  
2.2. AHR signaling 
The classical mechanism for AHR activation and signaling is presented in 
Figure 1. In its inactive form, the AHR resides in the cytoplasm in a complex with 
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two heat shock protein 90 (Hsp90) molecules, p23 and hepatitis B virus X-
associated protein (XAP2/AIP) (Murray et al. 2014).  It is proposed that the 
Hsp90 protein, which interacts with the bHLH and the PAS B domains of the 
AHR and masks the nuclear localization signal (NLS), is essential for retention of 
the AHR complex in the cytoplasm in a high affinity ligand-binding (Reisz-
Porszasz et al. 1994).  
 The AHR is found in the cytoplasm bound to the chaperone proteins. 
Upon ligand binding the AHR-chaperone complex undergoes a conformational 
change that reveals the nuclear localization sequence and allows translocation 
into the nucleus. In the nucleus, AHR dissociates from Hsp90 and dimerizes with 
another member of the bHLH/PAS family, AHR Nuclear Translocator (ARNT). 
The AHR-ARNT heterodimer combines with co-activators and co-repressors via 
its transactivation domain located at the C-terminal and binds to -cis elements of 
DNA containing consensus sequences, termed xenobiotic response elements 
(XRE) or dioxin response elements (DRE).  The heterodimer/DNA complex can 
modify transcriptional activity or chromatin structure and initiate transcription by 
recruiting RNA polymerase II (Murray et al. 2014).   
Classically studied genes that are regulated by the AHR include those that 
encode for xenobiotic metabolizing enzymes, such as cytochrome P450 
enzymes, glutathione-S-transferees, uridine diphosphoglucuronosyltransferases, 
NAD(P)H-dependent quinone oxydoreductase-1, and aldehyde dehydrogenase 
3A1. As will be discussed later, in recent years the set of genes under AHR 
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regulation has dramatically expanded (Nebert et al. 2000; Stejskalova et al. 
2011). 
AHR is now known to be involved in many additional molecular pathways 
distinct from the classical model of AHR signaling described above. These 
include ligand-independent AHR activation (Xiao et al. 2015), dimerization of the 
AHR with molecules other than ARNT, and cross-talk with other molecular 
pathways.  
A complex AHR ligand–dependent cross-talk exists between the AHR and 
ER. AHR has anti-estrogenic activity, which is thought to occur via several 
mechanisms, including competition for shared co-activators required for 
transcription regulation (squelching), direct inhibition of transcription from ER-
responsive genes, or binding the ER and recruiting it away from ER-responsive 
genes and towards AHR-responsive genes (Matthews and Gustafsson 2006).  
Cross-talk between the AHR and the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) pathways has also been a subject of much 
recent research. NF-kB proteins are transcription factors important in innate and 
adoptive responses, and so this cross-talk represents an intriguing connection 
between chemical detoxification and immune/inflammatory mechanisms. Recent 
data shows that, like AHR, as will be discussed later, the NF-kB proteins are also 
involved in cancer progression making the NF-kB-AHR link relevant in cancer. 
The AHR physically interacts with multiple NF-kB proteins, including RelA, RelB 
(Tian et al. 1999), c-Rel (Sulentic et al. 2000) and p50 (Puga et al. 2000), and the 
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resulting dimers modulate target gene expression.   
 Recent studies identified another non-canonical pathway of AHR 
activation in which AHR dimerizes with a putative tumors suppressor Kruppel-
Like Factor 6 (KLF6) and induces gene transcription by binding a nonconsensus 
response element in the promoter region of the target gene (Wilson et al. 2013).  
2.3. Regulation of AHR activity 
The level of AHR activity is determined primarily by type and availability of 
AHR ligands and further modulated by general regulatory mechanisms that are 
not dependent on identity of a ligand. Regulatory mechanisms may involve 
modulation of AHR protein levels or modulation of AHR target gene expression.  
Here we will outline the major known mechanism of AHR repression. 
One mechanism that regulates AHR activity is based on proteasome 
degradation. According to this model increased proteolysis of the AHR reduces 
AHR binding to the DNA, thus reducing AHR activity. It is proposed that when 
AHR binds a ligand, it enters the nucleus, dissociates from the chaperones that 
mask the nuclear export signal (NES), and shuttles between ligand-bound AHR 
and ligand-bound AHR-ARNT heterodimer. As the ligand-bound AHR exits the 
nucleus, it is ubiquitinated and degraded by proteasomes, shifting the equilibrium 
away from AHR-ARNT heterodimers and attenuating transcriptional activation of 
AHR-dependent genes (Pollenz 2002).  
The second way AHR activity can be regulated is by modulating the ability 
of available AHR to induce target gene transcription. Several mechanisms have 
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been described for this process, some of which include competition for AHR 
dimerization partners and trans-repression of AHR target genes. One major 
mechanisms of AHR repression involves regulation by the Aryl Hydrocarbon 
Receptor Repressor (AHRR).  The AHRR shares homology with the AHR in the 
N-terminal domain regions that are involved in dimerization to ARNT and binding 
to DNA. Unlike the AHR, however, the AHRR does not have a ligand-binding 
PAS-B domain (M. E. Hahn et al. 2009). The mechanism of AHRR-mediated 
suppression of AHR activity is complex and not entirely understood. Some 
studies propose that AHRR dimerizes with ARNT, binds to XRE in promoter 
regions of AHR-dependent genes and recruits co-repressors to attenuate gene 
expression (Oshima et al. 2007). However, experiments overexpressing ARNT or 
using mutant AHRR that is unable to bind to DNA indicate that AHRR-mediated 
AHR activity repression does not depend on competition for ARNT and is only 
partially dependent on direct AHRR-DNA interaction (Evans et al. 2008). Other 
proposed mechanisms include competition with AHR for a limiting coactivator 
necessary for transcription, or alternatively, preventing the AHR from binding 
necessary coactivators by direct interaction with AHR (M. E. Hahn et al. 2009). In 
normal conditions a negative feedback loop is thought to exist, in which the AHR 
transcriptionally induces the AHRR, leading to transcriptional down-regulation of 
AHR-dependent genes.   
2.4. Types of AHR ligands 
While AHR ligands share some common characteristics, including an 
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aromatic ring structure, a wide variety of AHR-activating compounds exist. AHR 
ligands can be classified based on the following characteristics: 1) the direction in 
which they affect AHR activity (up, down, or context-specific), 2) their mode of 
production (synthetic or natural) and 3) their source with respect to the cell they 
affect (made by the cell or from an exogenous source). 
 Based on the downstream effects of activation AHR ligands are classified 
as agonist, antagonist, or selective AHR modulators (sAHRms). Agonists bind to 
the AHR and lead to increased gene transcription. The AHR affinity of and type 
(full, partial) of agonist determines the degree of gene induction.  A partial 
agonist is one, which binds to the AHR but is not fully efficacious. In contrast, 
AHR antagonists bind the AHR, but competitively inhibit its activity. Agonist-
induced AHR activity is attenuated or inhibited in the presence of an AHR 
antagonist. Paradoxically, a partial AHR agonist may also act as an antagonist in 
the presence of a full AHR agonist due to competition of a partial agonist with the 
full agonist for the ligand binding. A ligand is termed a partial agonist of the AHR 
when it is capable of partially activating AHR on its own, but suppresses AHR 
activity in the presence of a full agonist (Soshilov and Denison 2014).  
Selective AHR modulators (sAHRm’s) are molecules that bind the AHR 
and alter gene expression independently of binding to DREs (Murray et al. 2010). 
sAHRm’s can have both agonist and antagonist activities, in a tissue selective 
manner (Jin et al. 2012). Some of the recently identified sAHRm’s are currently 
used pharmacological agents, including omeprazole, tranilast, sulindal and 
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leflunomide (Jin et al. 2012; Narayanan et al. 2012; Rzemieniec et al. 2015).  
One sAHRm, 6-methyl-1,3,-trichlorodibenzofuran (MCDF), is currently being 
investigated as a breast cancer therapeutic (Zhang et al. 2009). Existence of 
AHR ligands that can act in context-specific ways and induce DRE-independent 
AHR activity may have a therapeutic advantage, as new sAHRms with anti-tumor 
activities in the absence of the toxicities associated with other AHR modulators 
are developed.  
AHR ligands belonging to the major classes described above may further 
be grouped into synthetic or natural. Synthetic ligands can be synthesized for 
pharmacological purposes, or they can be formed as byproducts of industrial 
processes and released into the environment. Some of the strongest AHR 
agonists belong to the group of synthetic environmental pollutants such as 
polycyclic aromatic hydrocarbons (PAH), halogenated aromatic hydrocarbons 
(HAH) and polychlorinated biphenyls (PCB), which will be discussed below. 
Natural AHR ligands include natural plants-derived ligands and AHR ligands 
produced in situ by cells.   
Finally, AHR ligands are classified based on their source with respect to 
the cell they will affect. Ligands that enter the cell from a surrounding 
environment are exogenous AHR ligands. AHR ligands produced by the cells in 
which they bind the AHR are endogenous AHR ligands.   It is important to note 
that endogenous and exogenous ligands may induce different signaling 
pathways in a context-specific fashion (Schlezinger et al. 2006; Murray et al. 
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2014). For example, while environmental AHR ligands are often genotoxic and 
carcinogenic, in some contexts exogenous AHR ligands may reduce cancer cell 
invasion (Hall et al. 2010; Prud'homme et al. 2010; Zhao et al. 2012; S. Safe et 
al. 2013; Jin et al. 2014). The studies presented here investigate the effects of 
exogenous and endogenous AHR ligands on breast cancer progression 
specifically in the context of triple negative mammary epithelial mammary cancer 
cells.  
2.5. AHR and cell physiology 
The AHR originally gained notoriety for its role in environmental chemical 
sensing and metabolism (Ema et al. 1994). However, the scope of the known 
role of the AHR in mammalian physiology has quickly expanded, as 
accumulating evidence demonstrates that the AHR, like other PAS family 
members, plays a critical role in several important biological processes 
independent of environmental stimuli.  
AHR activity in the absence of exogenous ligands is referred to as 
‘constitutive’ activity. Early in vitro studies reported presence of AHR in nuclear 
extracts of human and mouse liver cancer cells. Further in vivo studies 
demonstrated that AHR-/- mice exhibit cardiovascular, hepatic, and reproductive 
abnormalities (P. Fernandez-Salguero et al. 1995; Schmidt et al. 1996; Andreola 
et al. 1997; Fernadez-Saluero et al. 1997; Abbott et al. 1999; Benedict et al. 
2000; Lahvis et al. 2000; Thackaberry et al. 2002; Vasquez et al. 2003; Lahvis et 
al. 2005; Barnett et al. 2007), have a propensity to develop colitis (Fernadez-
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Saluero et al. 1997), develop immune system deficiencies (Fernadez-Saluero et 
al. 1997; Kerkvliet 2009; Kimura et al. 2009), produce hematopoietic stem cells 
that are prone to stem cell exhaustion (K. P. Singh et al. 2009; K. P. Singh et al. 
2014), generate megakaryocytes of reduced ploidy (Lindsey and Papoutsakis 
2011), and make platelets that are defective in their ability to aggregate and to 
respond to collagen (Lindsey et al. 2014). Additional studies demonstrated that 
the AHR influences responses to hypoxia (Jensen et al. 2006), skewing of T cell 
subsets into TH17 and Treg cell subsets (Funatake et al. 2005; Quintana et al. 
2008; Apetoh et al. 2010; Gagliani et al. 2015), antigen-presentation (Mezrich et 
al. 2010; Nguyen et al. 2010), embryonic (Peters and Wiley 1995; Q. Wang et al. 
2013b) hematopoietic (Casado et al. 2011; Smith et al. 2013) stem cell 
differentiation and cell cycle (Q. Ma and Whitlock 1996; Weiss et al. 1996).  
These findings, together with the fact that the AHR is highly conserved 
throughout evolution (ME Hahn et al. 1997), are consistent with a physiological 
role of constitutively active AHR. 
 
2.6. Constitutive AHR activity and breast cancer 
Recent evidence suggests that the AHR plays a critical role in cancer 
progression in the absence of environmental ligands. AHR is hyper-expressed in 
several tumor types (S. Safe et al. 2013; Murray et al. 2014) including, 
glioblastomas (Gramatzki et al. 2009; Opitz et al. 2011), lymphomas (Sherr and 
Monti 2013), T cell leukemia (Hayashibara et al. 2003), and pancreatic 
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(Koliopanos et al. 2002; Jin et al. 2015), ovarian (K. Wang et al. 2013a), lung (J. 
T. Chang et al. 2007), liver (Z. Liu et al. 2013), and head and neck carcinomas 
(DiNatale et al.), and the AHR signaling appears to be constitutively active in 
these tumors (C. Y. Chang and Puga 1998; Roblin et al. 2004; Gramatzki et al. 
2009; DiNatale et al.).  
Evidence suggesting a role for the AHR in breast cancer in particular 
includes: 1) the high level of constitutively active AHR in many rodent and human 
breast cancer models and in primary tumors (F. Wang et al. 1999; D. W. Kim et 
al. 2000; Trombino et al. 2000; Larsen et al. 2004; Currier et al. 2005; 
Schlezinger et al. 2006; Barhoover et al. 2010; Korzeniewski et al. 2010; G. D. 
Goode et al. 2013; Z. D. Li et al. 2014), 2) an association between AHR activity 
and transcriptional up-regulation of genes associated with invasion (Belguise et 
al. 2007) and survival (Vogel et al. 2011), 3) AHR-mediated degradation of E-
cadherin (J. Y. Chen et al. 2014), 4) down-regulation of invasion and metastasis-
associated genes after Ahr knockdown (G. Goode et al. 2014), 5) inhibition of 
breast cancer cell line invasion, migration, metastasis or mammosphere 
formation in the presence of an AHR inhibitor (Parks et al. 2014) or after AHR 
knockdown (G. D. Goode et al. 2013; Zhao et al. 2013), and  6) acquisition of an 
invasive phenotype after over-expression of Ahr in non-malignant, non-invasive 
breast epithelial cells (Brooks and Eltom 2011).   
In addition to the evidence found by other groups, previous work in our lab 
strongly supports the role of constitutive AHR activity in breast cancer 
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progression. We have found that AHR expression and activity correlates with 
mammary epithelial growth rates and invasiveness. For example, we found that 
in BP1 cells, which are malignant cells derived from a non-malignant 
immortalized mammary epithelial cell line with DMBA treatment, AHR down-
regulation with shRNA significantly (p<0.05) increases mRNA expression for E-
cadherin, an adhesion molecule associated with a non-invasive, epithelial 
phenotype (5.1 fold) and decreases (p<0.05) fibronectin (3.7 fold), MMP1 (7.7 
fold), MMP13 (3.3 fold), and thrombospondin (5.2 fold) (data not shown). These 
changes are indicative of reversal of the invasive phenotype following AHR 
inhibition. Importantly, AHR down-regulation with AHRR, AHR siRNA, shAHR, or 
soluble AHR inhibitor, dramatically reduced BP1 and Hs578T invasion in Matrigel 
and Boyden chambers (data not shown). These data are consistent with reports 
of decreases in glioblastoma invasion after AHR down-regulation (Opitz et al. 
2011) and a correlation between transcriptional AHR activity in primary mouse 
and rat breast tumors and up-regulation genes associated with growth and 
invasion, including AHR target genes, CK2α  and Slug (Come et al. 2004; Elloul 
et al. 2005; Belguise et al. 2007). 
Our recent experiments involving AHR modulation demonstrated that AHR 
activity is associated with stem cell like properties, including expression in vitro, 
and mRNA expression in vivo, of ALDH1 (Stanford et al. 2016), a cancer stem 
cell marker linked to chemo-resistance and poor prognosis (Ginestier et al. 
2007).  Importantly, cancer stem cell properties are associated with invasion, 
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metastasis (Al-Hajj et al. 2003; Charafe-Jauffret et al. 2009; Charafe-Jauffret et 
al. 2010), chemo resistance and cancer relapse (Schulenburg et al. 2015). These 
results demonstrate the multi-faceted involvement of AHR in breast cancer 
progression and suggest a link between constitutive AHR activity and breast 
cancer in the context of chemo resistance and cancer relapse.  
The abundant evidence for the role of AHR activity in breast cancer 
progression and recurrence in the absence of exogenous ligands warrants 
investigation of what mechanisms are involved in constitutive AHR activity and 
how environmental AHR ligands may affect these mechanism.  
 
3. AHR ligands and breast cancer 
  3.1. Environmental AHR ligands and cancer 
According to the classical model for AHR-induced toxicity, once bound to 
a ligand, the AHR transcriptionally induces phase I and II xenobiotic-metabolizing 
enzymes of the cytochrome p450 family, which in turn metabolize environmental 
ligands to carcinogenic intermediates (Conney 1982; C. Ma et al. 2009). Given 
the recent evidence of AHR contributing to cancer progression via non-genotoxic 
mechanisms, activation of the AHR may be a key step in both the genotoxic and 
non-genotoxic carcinogenic effects of environmental AHR agonists. The following 
discussion will briefly describe three of the major groups of environmental AHR 
ligands:  polycyclic aromatic hydrocarbons (PAHs), halogenated aromatic 
hydrocarbons (HAHs) and polychlorinated biphenyls (PCBs). 
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PAHs form during incomplete combustion of hydrocarbons, fossil fuels 
(coal and gas), and biomass for energy production.  There are over 100 PAH’s 
produced by these processes, and they may persist in the atmosphere as 
complex mixtures.  PAHs exist as contaminants in automobile exhaust engines, 
plastics manufacturing waste and pesticides (Korsh et al. 2015). PAHs include 
benz(a)pyrene (BaP), dibenz(ah)anthracene (DB(ah)A), 1-nitropyrene (1-NP), 
and 7,12-dimethylbenz(a)anthracene (DMBA) (Korsh et al. 2015).  Human 
exposure to PAHs may occur via inhalation of polluted air or cigarette smoke, 
consumption of PAH-containing burnt or smoked meats or absorption through the 
skin.  
In vitro studies indicate that metabolites of PAHs affect growth and repair 
mechanisms and promote acquisition of characteristics associated with invasion 
and metastasis, such as anchorage independence (Calaf and Russo 1993).  
Similarly, PAHs have been shown to induce mammary tumors in animals (el-
Bayoumy et al. 1988; Hecht 2002).  Due to the lipophilic properties of PAH’s, 
these chemicals can accumulate in mammary fat tissue, making breasts 
susceptible to PAH-driven carcinogenesis. One of the methods for assessing the 
relationship between PAH exposure and breast cancer risk is measuring the level 
of PAH-DNA adducts in tumor samples vs. healthy tissue. Several studies have 
detected higher levels of PAH-DNA adducts in tumor tissue compared to healthy 
mammary epithelial tissue (D. Li et al. 1996; Gammon et al. 2004), or compared 
to benign breast disease (Rundle et al. 2002), suggesting that PAHs contribute to 
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breast cancer development in humans.  
HAHs are a large class of teratogenic structurally-related environmental 
pollutants. While some HAH’s may be produced naturally, industrial processes 
have been a major source of these pollutants in the past two centuries (White 
and Birnbaum 2009).  Examples of HAHs include polychlorinated biphenyls 
(PCBs), halogenated dibenzofurans, and halogenated dibenzo-p-dioxins 
(PCDD). Those HAHs that are structurally similar to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) and bind to the AHR are termed dioxin-like compounds.  Dioxins 
and dioxin-like compounds belong to the persistent organic pollutant class of 
chemicals, which are lipophilic, long lived in the environment, and are resistant to 
metabolism. Dioxins and dioxin-like compounds bioaccumulate and biomagnify in 
the food chain. They enter the human diet through via consumption of fatty foods, 
in particular (Tavakoly Sany et al. 2015).  
TCDD was the first identified and the most potent AHR ligand, a multisite 
carcinogen, a toxicant and a teratogen.  Studies in AHR-knockout mice (P. M. 
Fernandez-Salguero et al. 1996) or mice harboring a mutation in the nuclear 
localization region (NLS) (Bunger et al. 2003) of AHR have shown that most of 
the toxicity of TCDD is AHR-dependent. Unlike other AHR ligands, TCDD is not 
rapidly metabolized by the body and may accumulate in the body with a half-life 
of 5 – 11 years in humans (Milbrath et al. 2009; Tavakoly Sany et al. 2015).  
Consistent with this, many adverse effects of TCDD exposure are observed over 
the long-term (Poland and Knutson 1982; S. H. Safe 1995), and are likely to 
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result from continuous induction of AHR-dependent genes (Denison and Nagy 
2003). At this time, overall epidemiological evidence of the link between TCDD 
exposure and breast cancer risk inconclusive. However, several studies suggest 
that such a link exists.  One commonly studied cohort consists of residents of 
Seveso, Italy, where an accident in 1976 caused the contamination a large 
population with TCDD. While early studies of breast cancer risk in this population 
was inconsistent, an independent study found that women with breast cancer 
within this population had a higher medium serum level of TCDD (Warner et al. 
2002). Another study in 2009 found an elevated risk of breast cancer in females 
living close to the accident.  Given this evidence and the fact that TCDD is an 
established experimental carcinogen (Baan et al. 2009), the link between TCDD 
exposure and breast cancer deserves farther investigation. 
In the United States PCBs are currently not produced, but are present in 
materials produced before they were banned in 1979.  It is estimated by the 
Environmental Protection Agency (EPA) that over 1.5 billion tons of PCBs were 
produced before the ban (Breivik et al. 2002). PCB-containing products include 
including transformers, capacitors, adhesives, flame-retardants, insulators, motor 
oil and oil paints (White and Birnbaum 2009). These chemicals can be released 
into the environment from inappropriate maintenance of PCB-containing 
hazardous waste (White and Birnbaum 2009). A subset of PCBs has dioxin-like 
properties. In the environment PCB’s are usually found as mixtures that contain 
dioxin-like PCBs and TCDD (White and Birnbaum 2009). 
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PCB’s have been demonstrated to cause many illnesses including cancer 
in animals and are probable carcinogens in humans (National Toxicology 2006; 
Faroon and Ruiz 2015). Two comprehensive epidemiological literature reviews 
concluded that the data on the link between PCB exposure and breast cancer in 
women is inconsistent (Brody et al. 2007; Golden and Kimbrough 2009). 
However, the methods used in the epidemiological studies reviewed did not 
account for exposures at developmental times during which mammary glands are 
particularly sensitive (Verner et al. 2011). While many studies have focused on 
the link of total PCB exposure to breast cancer, a few studies have found 
increased levels of specific types of PCB’s in breast cancer patient blood and 
mammary tissue, compared to healthy controls (Charlier et al. 2004) (Aronson et 
al. 2000). Additionally, new evidence suggests that a link between PCB exposure 
and breast cancer risk is revealed when women are stratified by into groups that 
reflect differences in susceptibilities (Silver et al. 2009).   
3.2. Natural exogenous AHR ligands 
Natural AHR ligands can form in plants or, as will be discussed further in 
the next section, can be synthesized by mammalian or bacterial cells. Recent 
studies have identified numerous naturally occurring AHR agonists and 
antagonists in vegetables, fruits, teas and herbs. These ligands may be directly 
derived from plant, or synthesized in the body from plant-derived chemicals after 
consumption.  Naturally occurring plant-derived ligands include indole-3-
complexes (Bjeldanes et al. 1991; S. S. Singh et al. 1996; C. Y. Chang and Puga 
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1998), 7,8-dihydrorutacarpine (Gillner et al. 1989), dibenzoylmethanes 
(MacDonald et al. 2001), curcumin (Ciolino et al. 1998), carotinoids (Astorg et al. 
1994; Gradelet et al. 1996), flavonoids (Yannai et al. 1998; Ashida et al. 2000) 
and tryptophan metabolites such as indigo and indirubin (Phelan et al. 1998; 
Adachi et al. 2001). Some of these ligands may be metabolically converted in the 
human gut to more potent AHR ligands. For example I3C, which is found in 
cruciferous vegetables, condenses in the acidic environment of the gut into 
indolo [3,2-b] carbazole (ICZ) or 3’-diindolylmethane, both potent AHR ligands 
(Bjeldanes et al. 1991). Unlike most environmental AHR ligands that result from 
human activity and industrial processes, many naturally occurring AHR ligands 
exhibit cancer-preventative properties (Aggarwal and Ichikawa 2005; Martinez-
Perez et al. 2014). 
3.3. Natural endogenous AHR ligands  
Evidence of constitutive AHR activity in normal cell physiology and disease 
has drawn new attention to the identification of endogenous AHR ligands.   Some 
of the major classes of proposed endogenous AHR ligands include tetrapyroles, 
arachidonic acid metabolites and tryptophan metabolites. Tetrapyroles that were 
shown to induce DRE-regulated reporter genes in vitro include the heme 
metabolites bilirubin and billiverdin (Sinal and Bend 1997).  Given that these 
metabolites are metabolized by AHR-dependent P450 enzymes, it is proposed 
that there is a self-regulatory negative feedback loop in which these AHR ligands 
control their own metabolism.  Arachidonic acid metabolites, including 
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Leukotriene A 4 (5,6-LTA 4) metabolites, induce AHR activity in vitro. Some 
studies propose that as a way in which the AHR may regulate inflammation 
(Chiaro et al. 2008). A direct physiological link between arachidonic acid 
metabolites and AHR activity has yet to be established.   
Tryptophan metabolism has recently emerged as a source of potential 
endogenous AHR ligands. Tryptophan is an essential amino acid found mainly in 
milk, cheese, yogurt, egg, spirulina, chicken, turkey, pork, salmon, potatoes and 
bananas (Chung and Gadupudi 2011). A tryptophan photo-oxidation indole 
product formylindolo [3,2-b]carbazole (FICZ), which has a high affinity for the 
AHR and has been detected in human keratinocytes and urine (Fritsche et al. 
2007; Wincent et al. 2009), contributes to the stress response to UVB in animals 
(Rannug et al. 1995; Dhir et al. 1999; Wei et al. 2000; Fritsche et al. 2007). 
Metabolites produced via the tryptophan pathway have been identified as AHR 
ligands. Several have been associated with physiological effects, as discussed in 
further detail below. Recently, Opitz et al identified kynurenine as an endogenous 
AHR ligand responsible for tumor invasiveness in human glioblastoma (Opitz et 
al. 2011). Another study showed that the downstream product of kynurenine, 
kynurenic acid, can induce IL-6 expression via the AHR, at concentrations similar 
to those found in the normal gut of animal models(DiNatale et al. 2010). This 
project focuses on products of tryptophan metabolism as potential source of 
endogenous AHR ligands capable of promoting cancer progression in mammary 
epithelial cells.  
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4. Tryptophan metabolism and the AHR in breast cancer 
4.1. Overview of tryptophan metabolism and breast cancer. 
 
As early as the 1970’s, elevated excretion of tryptophan metabolites in 
urine has been associated with breast cancer or its poor prognosis (DeGeorge 
and Brown 1970; Fahl et al. 1974). Since then, metabolomics profiling studies 
have consistently reported abnormal levels of tryptophan metabolites, indicative 
of increased rates of tryptophan metabolism, in urine and blood of breast cancer 
patients (Y. Chen et al. 2009; Lyon et al. 2011).  Given these observations, 
studying the mechanisms that link abnormal tryptophan metabolism to breast 
cancer is promising for identification of new therapeutic and prognostic 
strategies. 
 While tryptophan metabolism in humans consists of numerous steps and 
products, four main branches can be distinguished for the purposes of this 
discussion: 1) the serotonin branch, 2) the tryptamine branch, 3) the microbiome-
dependent indole branch and 4) the kynurenine branch (Figure 2). The following 
section will summarize these branches and the current state of knowledge on 
physiological significance of these pathways, focusing on the context of breast 
cancer and AHR activation.  
4.2. The kynurenine branch.  
The kynurenine branch of tryptophan metabolism is represented in the 
lower left of Figure 2. The kynurenine is the dominant pathway in tryptophan 
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metabolism and accounts for nearly 90% of metabolism in humans (Chung and 
Gadupudi 2011). Under normal conditions most of the kynurenine production 
takes place in the liver. Multiple studies have shown that the kynurenine pathway 
is a source of endogenous AHR ligands (Heath-Pagliuso et al. 1998b; Mezrich et 
al. 2010; Nguyen et al. 2010; Chung and Gadupudi 2011; Opitz et al. 2011). 
The rate-limiting step in the kynurenine pathway is the conversion of L-
tryptophan to N-formyl-kynurenine by tryptophan 2,3 dioxygenase (TDO) or 
indoleamine 2,3 dioxygenase 1/2 (IDO1/2) (Opitz et al. 2011; van Baren and Van 
den Eynde 2015). N-formyl-kynurenine is then hydrolyzed to L-kynurenine 
(herein referred to as kynurenine), which is metabolized further into kynurenic 
acid (KA) and xanthurenic acid (XA), all three of the latter being inducers of AHR 
activity (DiNatale et al. 2010).   As will be discussed later, the majority of studies 
investigating the link between kynurenine branch of tryptophan metabolism and 
breast cancer focus on the role of KYN, and the kynurenine pathway rate limiting 
enzymes, in tumor immunity.  Studies on the role of downstream kynurenine 
metabolites, XA and KA, in cancer are relatively scarce. XA is reportedly a 
bladder and lymphoreticular system carcinogen in mice (Bryan 1969; Lower and 
Bryan 1969), and elevated XA has been detected in urine of bladder cancer 
patients (Bryan 1969). Abnormal kynurenic acid production has been associated 
with colon (Walczak et al. 2011) and pancreatic (Botwinick et al. 2014) and lung 
cancers (Sagan et al. 2012; Sagan et al. 2015). However, the link between XA or 
KA and breast cancer has not been investigated. 
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While IDO and TDO catalyze the same step, these two enzymes differ 
with respect to expression patterns in the body, substrate specificity, cofactor 
requirement and mechanisms regulating expression and activity (van Baren and 
Van den Eynde 2015). IDO is expressed throughout the body, except in the liver, 
and has a wider substrate specificity compared to TDO (Sono et al. 1996). Under 
normal physiological conditions IDO has a low baseline activity, but it is highly 
induced by several inflammatory factors, most notably IFN-gamma. IDO activity 
is up-regulated during inflammatory processes, at sites of infections and tumor 
growth (Chung and Gadupudi 2011).  IDO was initially studied for its function in 
the placenta, where it contributes to immunosuppression in part through 
induction of regulatory T cells (Munn et al. 1998; Mellor et al. 2001). More recent 
evidence reveals that IDO plays an important role in multiple forms of acquired 
peripheral tolerance, including solid organ allograft tolerance (Guillonneau et al. 
2007; Lan et al. 2010; Sucher et al. 2012), mucosal tolerance (van der Marel et 
al. 2007; Matteoli et al. 2010), tolerance to apoptotic cells (Ravishankar et al. 
2012), and it curbs inflammation in chronic disease (Szanto et al. 2007; Romani 
et al. 2008). Importantly, IDO is expressed in a variety of tumors where it 
contributes to an immunosuppressive environment and tumor immune evasion. 
Consequently, IDO is currently studied as an immunotherapy target and several 
IDO inhibitors are in clinical trials for breast, lung, ovarian and other cancers 
(Munn and Mellor 2016).   
Unlike IDO, TDO expression in humans is normally restricted to the liver, 
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where it is responsible for most of the dietary tryptophan metabolism (van Baren 
and Van den Eynde 2015). TDO expression is up-regulated by tryptophan and 
adrenocorticosteroids, estrogen and androgens (Rose 1972). TDO activity can 
be elevated upon exposure to glucocorticoids (Knox 1951) as well as tryptophan. 
TDO is abnormally over-expressed in a large proportion of human tumors (Opitz 
et al. 2011), as well as a number of human tumor cell lines (Salter et al. 1995; 
Pilotte et al. 2012). Much research has been done to study the role of TDO in 
tumor immunity (Opitz et al. 2011; Pilotte et al. 2012). As with IDO, TDO may 
mediate tumor immunity either via tryptophan depletion or via production of 
tryptophan catabolites (Lob et al. 2009; van Baren and Van den Eynde 2015).  
Recently the role of TDO in promoting tumor growth and invasion has 
begun to emerge. TDO promotes tumor growth and invasion in vitro and tumor 
growth in vivo through AHR activation by kynurenine in glioblastoma (Opitz et al. 
2011). To date, only this study has demonstrated that an endogenous AHR 
ligand is present at physiologically relevant concentrations in human cancer cells, 
where it contributes to cancer progression. One recent study has looked at the 
role of TDO in triple negative breast cancer progression, showing that TDO 
inhibition decreases anoikis resistance, proliferation, migration, invasion and in 
vivo growth of TNBC (D'Amato et al. 2015a). It was also found that multiple 
enzymes of the kynurenine pathways, including TDO, are up-regulated in TNBC 
cell suspensions. However, while kynurenine was detected in cell extracts, it was 
not found to be present at physiologically active concentrations, and no other 
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downstream products of kynurenine metabolism were assayed. Nevertheless, 
given the roles of TDO in tumor immunity as well as tumor growth, this enzyme 
may present an important chemotherapeutic target.  
4.3. The tryptamine branch  
The tryptamine branch of tryptophan metabolism involves conversion of 
tryptophan to indole-acetic-acid, via tryptamine (Figure 2, upper right). 
Tryptamine and indole-acetate induce nuclear translocation of the AHR complex 
(Heath-Pagliuso et al. 1998a), although a more recent study suggests that 
tryptamine is a pro-ligand of the AHR (Vikstrom Bergander et al. 2012). Of note, 
tryptamine is a competitive substrate for CYP1A1 (Chiaro et al. 2007), which is 
transcriptionally regulated by the AHR. This presents a possibility that up 
regulation of CYP1A1 by increased AHR activity may result in metabolism of 
potent AHR ligands formed in the tryptamine branch of tryptophan metabolism. 
Given the ability of tryptamine pathway metabolites to act as AHR ligands, further 
studies are needed to investigate the potential link between this branch and AHR 
activity in breast cancer. 
4.4. The serotonin branch 
The serotonin branch of tryptophan metabolism is shown in the upper left 
portion of Figure 2. Serotonin (5-hydroxytryptamine) is a neurotransmitter formed 
from L-tryptophan in a two-step process that is dependent on the rate limiting 
enzyme tryptophan hydroxylase. In humans, 95% of serotonin is contained in 
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enterochromaffin cells of the digestive tract, from which it can be released into 
plasma and taken up by platelets (Chung and Gadupudi 2011). Serotonin is also 
synthesized in the nervous system.  In the brain, serotonin can be further 
metabolized to melatonin and hydroxyl-melatonin (Figure 2, upper left).  
Serotonin and its downstream metabolites exhibit weak to no AHR agonist 
activity (Bittinger et al. 2003; Quintana and Sherr 2013).  However, an indirect 
link may exist between AHR activity and the serotonin pathway due to the fact 
that CYP1A1 and CYP1B1 mediate conversion of melatonin to 6-
hydroxymelatonin. Therefore, AHR-mediated transcriptional up-regulation of 
Cyp1A1 and Cyp1B1 expression may result in a metabolic sink that would 
reduce tryptophan availability for other branches of metabolism, including those 
branches that generate potent AHR ligands (Quintana and Sherr 2013). 
Conversely, elevated levels of the serotonin branch metabolites upstream of 
CYP1A1 may compete with potent AHR ligands that are also CYP1A1 
substrates, such as tryptamine, leading to ligand accumulation.   
Little research has been done on the role of the serotonin branch of 
tryptophan metabolism and breast cancer. Recently, serotonin released from 
platelets in the thrombotic environment of the tumor has been linked to 
angiogenesis and tumor growth (Banskota et al. 2016). A study of 2000 breast 
cancer metabolic profiles identified excess serotonin production as a major 
predictor of poor prognosis (Leoncikas et al. 2016).  While no direct link between 
serotonin and breast cancer has been found, these findings implicate 
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deregulated tryptophan metabolism in breast cancer progression. 
4.5. The indole branch.  
The microbiome-dependent metabolism pathway (Figure 2, lower right) 
involves conversion of tryptophan to indole by tryptophanase present in gut 
bacteria (Figure 2, lower right). Indole reaches the liver via hepatic circulation, 
where it is converted to indoxyl sulfate (IS), which is then delivered into the blood 
stream (Wikoff et al. 2009). IS induces AHR activity in hepatocytes and 
competitively binds to the AHR (Schroeder et al. 2010). IS has been shown to 
induce characteristics typical of EMT in renal tubular cells (S. H. Kim et al. 2012; 
Vikstrom Bergander et al. 2012), and its accumulation due to abnormal gut 
microbiome has been implicated in colon cancer (Bolati et al. 2011). 
IS is a uremic toxin, and it accumulates at micromolar concentrations in 
the serum of kidney dialysis patients (Schroeder et al. 2010). It is suggested that 
AHR activation plays a role in IS-induced kidney damage (Ichii et al. 2014) and 
cardiovascular system damage (Sallee et al. 2014; Ito et al. 2016). Importantly, 
elevated IS is reported in acute kidney injury induced by cisplatin in rats (Uehara 
et al. 2014). This is of particular significance for breast cancer because platinum-
based drugs, including cisplatin, used for TNBC treatment (Petrelli et al. 2014), 
lead to acute nephrotoxicity in cancer patients (Hartmann et al. 2000).  
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OVERVIEW AND HYPOTHESIS 
Historically, AHR has been studied for its role in carcinogenesis involving 
P450 enzyme induction and genotoxicity in the presence of PAH ligands of AHR.  
Abundant recent evidence indicates that AHR is essential for many normal 
physiological processes in the absence of environmental AHR ligands and that 
abnormal AHR activity contributes to cancer progression via non-genotoxic 
molecular mechanisms.  
Our previous studies showed that AHR expression and activity are up - 
regulated in rat tumors induced with DMBA (unpublished) as well as in human 
breast cancer cells (X. Yang et al. 2008). These findings lead to a question: What 
endogenous ligands contribute to AHR-driven cancer progression and how can 
environmental AHR ligands affect or mimic this process? Several tryptophan 
metabolites have been reported to be potent AHR ligands. This observation, 
together with the fact that aberrant tryptophan metabolism has long been 
associated with breast cancer (DeGeorge and Brown 1970; E. M. Bell et al. 
1971; Davis et al. 1973; Fahl et al. 1974; E. D. Bell et al. 1975; Lehrer et al. 
1988; Cascino et al. 1991; Cascino et al. 1995; Y. Chen et al. 2009; Chung and 
Gadupudi 2011; Lyon et al. 2011) peaked our interest in the possible link 
between tryptophan metabolism and AHR activity in breast cancer. To 
investigate the possible role of tryptophan metabolites as endogenous AHR 
ligands, our laboratory tested a panel of tryptophan metabolites for AHR agonist 
activity in mammary epithelial cells. Four potent AHR agonists were identified, 
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belonging to two major tryptophan metabolism branches: 1) the kynurenine 
branch (kynurenine (KYN), kynurenic acid (KA), xanthurenic acid (XA)) and 2) 
the microbiome-dependent indole branch (indoxyl sulfate (IS)). Table 1 
summarizes the current state of knowledge on the role of these metabolites in 
cancer and their ability to activate the AHR.  Our finding lead to a central 
hypothesis: Tryptophan metabolites drive constitutive AHR activity and thereby 
enforce cell growth and/or invasion of malignant human mammary epithelial 
cells. As a corollary, it was postulated that environmental AHR ligands mimic 
and/or distort this signaling. Two specific aims were proposed:  
Aim 1. Identify endogenous AHR ligand(s) responsible for AHR-dependent 
human mammary epithelial cell migration.  
Metabolomic analysis was used to determine the presence of AHR-inducing 
tryptophan metabolites in malignant cells, focusing on the KYN and IS synthesis 
pathways. The ability of these metabolites to increase cell migration and ALDH 
activity, in an AHR-dependent fashion, was tested.  
Aim 2. Define the contributions of key enzymes in the KYN pathway to cell 
malignancy via endogenous AHR ligand production and determine the role of 
AHR in regulation of these metabolic pathways. 
Gene knockdown and overexpression techniques, a rapid colorimetric 
KYN assay, (how were AhR activity and cell migration tested?) were used to 
determine the effect of key enzymes in the KYN pathway on KYN production, 
AHR activity and cell migration.  
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INTRODUCTION FIGURES 
Introduction, Figure 1: AHR activation and signaling 
 Overview of classical mechanism of AHR signaling. In the naïve state, the 
AHR is bound by several chaperone proteins. Exogenous or endogenous AHR 
ligand binds to the AHR, exposing a nuclear localization signal that allows the 
AHR to enter the nucleus. In the nucleus the ligand-bound AHR binds to ARNT 
and the dimer acts as a transcription factor, modulating target gene expression at 
Xenobiotic Response Elements (XREs). Additional abbreviations: heat shock 
protein 90 (Hsp90), hepatitis B virus X-associated protein (XAP2), aryl 
hydrocarbon receptor nuclear transporter (ARNT).  
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Introduction, Figure 1.  
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Introduction, Figure 2: Main branches of tryptophan metabolism 
 
  Kynurenine, Serotonin, Tryptamine and Microbiome-dependent Indole 
pathways of tryptophan metabolism are presented. Enzymes are in italics. 
Abbreviations for the serotonin branch: tryptophan hydroxylase (THP), dopamine 
decarboxylase (DDC, also present in tryptamine pathway), N-acetylserotonin O-
methyltransferase (ASMT). Abbreviations for the kynurenine branch: indolamine-
2,3-dioxygenase (IDO), tryptophan-2.3-dioxygenase (TDO), kynurenine 
aminotransferase (KAT). Abbreviations for the tryptamine branch: monoamine 
oxidases A and B (MAOA/MAOB), aldehyde dehydrogenase 2 (ALDH2). 
Abbreviations for the microbiome - dependent indole branch: cytochrome P450 
2E1 (CYP2E1), sulfotranferase 2 (SULT2). 
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Introduction, Figure 2  
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Introduction, Table 1. AHR-inducing tryptophan metabolites. 
 Tryptophan metabolites found to significantly induce AHR activity in a 
DRE-driven reporter assay screen, their pathway of origin, structures, major 
metabolic enzymes, and known literature on AHR activation and link to cancer 
are summarized. Abbreviations include: tryptophan-2,3-dehydrogenase (TDO), 
indolamine-2,3-dehydrogenase (IDO), kynurenine aminotransferase (KAT), 
cytochrome P450 2E1 (CYP2E1) and sulfotranferase 2 (SULT2). 
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METHODS 
Chemicals 
Dimethylsulfoxide (DMSO), 2,3,7,8-tetrachlorodibenzo[p]dioxin (TCDD), 
tryptophan, KYN, XA acid and KA were obtained from Sigma-Aldrich (St. Louis, 
MO). Puromycin was obtained from Invitrogen (Grand Island, NY). 6-
Formylindolo[3,2-b]carbazole (FICZ) and CH223191 were synthesized and 
generously provided by Dr. M. Pollastri (Northeastern University). 
Cell culture and media  
MCF10F (purchased from ATCC, Manassas, VA) and BP1 (invasive 
tumor-forming cells generated by treatment of MCF10F cells with B[a]P (Calaf 
and Russo 1993)) cells were cultured according to ATCC recommendations but 
without cholera-toxin and with 100 IU/ml penicillin, 100 µg/ml streptomycin 
(Mediatech) and 5 µg/ml plasmocin (Invivogen, San Diego, CA). MDA-MB-231 
cells (purchased from ATCC) were maintained in DMEM Medium (Mediatech, 
Hernon, VA) containing 10% FCII (Hyclone), 100 IU/ml penicillin, 100 µg/ml 
streptomycin (Mediatech) and 2 mM L-glutamine (Mediatech). MDA-MB-231-BO 
cells, a luciferase-expressing bone-seeking metastatic line derived from the 
MDA-MB-231 line (Yoneda et al. 2001; Wetterwald et al. 2002), were a generous 
gift from Dr. Gabri van der Pluijm (Leiden University Medical Center). MDA-MB-
231-BO cells were cultured as MDA-MB-231, with the addition of 800 µg/ml of 
Geneticin (Invitrogen). Hs578T cells, obtained from the ATCC, were maintained 
in F-12 Medium (Mediatech, Herndon, VA) containing 10% FBS (Sigma-Aldrich), 
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19.4 mM D-glucose (Sigma, cell culture tested), 100 IU/ml penicillin, 100 µg/ml 
streptomycin (Mediatech), 5 µg/ml plasmocin (Invivogen), 2 mM L-glutamine 
(Mediatech) and 10 µg /ml insulin (Sigma). HCC202 cells were a generous gift 
from Dr. Neil Ganem (Boston University) and were maintained in DMEM Medium 
(Mediatech, Hernon, VA) containing 10% FCII (Hyclone), 100 IU/ml penicillin, 
and 100 µg/ml streptomycin (Mediatech). SUM149 cells were a generous gift 
from Dr. Stephen Ethier (Wayne State University, Detroit, MI) and were 
maintained in F-12K Medium (Mediatech) containing 5% FBS (Sigma-Aldrich), 
0.5 µg/ml hydrocortisone (Sigma-Aldrich), 2 mM L-glutamine (Mediatech), 100 
IU/ml penicillin, 100 µg/ml streptomycin (Mediatech), 10 µg/ml insulin (Sigma-
Aldrich), and 5 µg/ml plasmocin (Invivogen). Stably transduced Hs578T and 
SUM149 cells were maintained in culture containing 1.5 µg/ml puromycin and 
transferred to puromycin-free medium three to five days prior to experiments. 
Culture conditions were maintained at 370C, 5% CO2. Use of these cell lines was 
determined to be Not Human Subjects Research. 
 
RT-qPCR  
mRNA was extracted using the RNeasy® Plus Mini Prep Kit (Qiagen, 
Valencia, CA), and cDNA prepared using the GoScript™ Reverse Transcription 
System (Promega, Madison, WI) with a 1:1 mixture of random and oligo (dT)15 
primers. RT-qPCR reactions were performed using the GoTaq® RT-qPCR 
Master Mix System (Promega). Validated primers were purchased from Qiagen 
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Inc. (Valencia, CA): human Cyp1b1 - QT00209496, Tdo2 - QT00027902, 18S - 
QT00225897, Ido1- QT00000504, Ido2 -QT01662920. RT-qPCR reactions were 
performed using a 7900HT Fast Real-Time PCR instrument (Applied Biosystems, 
Carlsbad, CA) with hot-start activation at 95° C for 2 min, 40 cycles of 
denaturation (95° C for 15 sec) and annealing/extension (55° C for 60 sec). 
Relative gene expression was determined using the Pfaffl method (Pfaffl 2001), 
and the threshold value for 18S RNA for normalization. No significant difference 
in 18S expression across samples was observed.  
Protein extraction and western immunoblotting 
Cells were grown to 70% confluence in T75 (75 cm2) flasks and harvested 
with trypsin. The cells were lysed in RIPA buffer (Fisher) containing protease and 
phosphatase inhibitors (Sigma/Aldrich). Immunoblotting was performed as 
previously described (Parks et al. 2014). Blots were incubated overnight with 
TDO-specific antibody produced in rabbit (1:1000, SAB1411338) and with β-
actin-specific antibody (1:2000, A5441) (Sigma/Aldrich), to control for loading 
variability.   
Liquid chromatography/mass spectrometry (LC/MS) analysis.  
To prepare metabolite extracts from cell lysates, Hs578T cells were 
cultured in 225 cm3 flasks for 4 days, and metabolite extraction was performed 
using an 80% (vol/vol) cold methanol extraction method (Yuan et al. 2012). To 
determine extraction efficiency, a spiked cell lysate sample was prepared by 
addition of recovery standards after the cells were harvested in ice-cold methanol 
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and transferred to 15 mL conical tubes. To determine sample concentration, 
titrated doses of recovery standards were dissolved in 80% (vol/vol) cold 
methanol. Final extracts and standards were lyophilized and stored in -80o C until 
further analysis.  
For tandem LC/MS analysis, a triple quadrupole linear ion trap mass 
spectrometer (3200 TRAP, AB Sciex, Foster City, CA), coupled to a binary pump 
HPLC (1200 Series, Agilent, Santa Clara, CA) was used. Chromatographic 
separation was achieved based on hydrophilic interaction on an aminopropyl 
column (Luna 5 µm NH2 100 Å 250 mm × 2 mm, Phenomenex, Torrance, CA) 
using a solvent gradient method. Solvent A was a solution of ammonium acetate 
(20 mM) and ammonium hydroxide (20 mM) in water with 5% acetonitrile (v/v) 
(pH 9.45)(Bajad et al. 2006). Solvent B was neat acetonitrile. The following 
gradient was used: t=0, 85% B; t=15 min, 100% B; t=28 min, 100% B; t= 30 min, 
15% B; t=50 min, 15% B. Prior to sample analysis, MS parameters were 
optimized by direct infusion with KYN, XA, KA and IS using commercial 
metabolite solutions (10 µm in MS-grade DI water). The mass analyzer was 
operated in negative ion mode for KYN, KA and IS and in positive mode for XA. 
The following mass transitions were used in the MRM scans and for 
quantification: KYN: m/z 207.0>143.8, KA: m/z 187.9>143.8, XA: m/z 
206.0>160.0. The principle of compound identification using triple quadruple 
mass spectrometer is summarized in Aim 1 Results section.  
For sample analysis, each lyophilized cell extract pellet was dissolved in 
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50–80 µL of MS-grade DI water. Peak identification and integration were 
performed using Analyst software (version 1.6, ABSciex, Foster City, CA). 
Sample concentrations were determined from standard curves for each 
metabolite. Intracellular concentrations were determined using the number of 
cells from which extracts were prepared and an approximate mammalian 
epithelial cell volume of 2000 µm3 (2010; Milo et al. 2010). 
Colorimetric kynurenine assay 
 Cell supernatants collected over 4 days from untreated cells were stored 
at -200 C until colorimetric analysis. For analysis, 160 µL of supernatant was 
added to 96-well culture plate and mixed with 10 µL/well of 30% (v/v) freshly 
prepared trichloroacetic acid (TCA). The plate was incubated at 500 C for 30 
minutes to hydrolyze N-formyl-kynurenine to kynurenine and then centrifuged at 
3000 x g for 10 minutes. Supernatant-TCA solution (100 µL) was transferred to a 
flat-bottom 96-well black plate and mixed with 100 µL of freshly prepared 
Ehrlich’s reagent (1.2% w/v 4-dimethylamino-benzaldehyde in glacial acetic 
acid). The plate was incubated for 10 minutes at room temperature, and 
absorbance was read with a micro plate reader at 492 nm (Synergy2, Biotek Inc). 
Culture medium that was not exposed to cells was used as time 0 supernatant.  
ALDEFLUOR™ staining 
ALDEFLUOR™ assays were performed according to the manufacturer’s 
instructions (StemCell Technologies, Vancouver, Canada). Cells were treated 
with 5 µl/ml ALDEFLUOR substrate in staining buffer provided in the kit. Negative 
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controls were treated an ALDH-specific inhibitor, diethylaminobenzaldehyde 
(DEAB, 50 mmol/L). Samples were incubated for 40 minutes at 37° C, washed 
with staining buffer and assayed with an LSRII flow cytometer (Becton Dickinson 
Biosciences, San Jose, CA). Data was gated and analyzed with FlowJo Software 
(FlowJo, Ashland, OR), using DEAB controls as baselines.  
Stable cells expressing shTdo2 and Tdo2  
Lentivirus preparation and transduction were performed according to the 
manufacturer’s protocol. Lentivirus-based Tdo2 shRNA (TRCN0000064900), 
control plasmid (SHC016 1EA) and lentiviral packaging mix were purchased from 
Sigma (St. Louis, MO, USA). Tdo2 Lentiviral Vector (pLenti-GIII-CMV-Human-
TDO2-GFP-2A-Puro Lentiviral Vector, LV332282) was purchased from Applied 
Biological Materials Inc. (Richmond, BC. CANADA). Control, shTdo2, or Tdo2 
plasmids were co-transfected with the packaging plasmids into 293T cells using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Forty-eight hours after 
transfection, the virus-containing supernatants were harvested and centrifuged at 
3,000 rpm for 15 min, and filtrated through a 0.45 µm low protein-binding filter 
(Millipore, Bedford, MA). Hs578T and SUM149 cells were infected with lentivirus 
(3 MOI) in the presence of hexadimethrine bromide (5 µg/mL polybrene, Sigma-
Aldrich) and fed with fresh complete medium the next day. Seventy-two 
hours after infection, the transduced cells were selected by puromycin (2 µg/ml). 
Efficiency of TDO knockdown or overexpression was validated by qRT-PCR and 
immunoblot analyses. Cells were cultured thereafter in 1.5 µg/ml puromycin, and 
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changed to puromycin-free medium three to five days prior to each experiment.  
Stable, doxycycline-inducible Ahr-specific shRNA-expressing cells 
Doxycycline (dox)-inducible TurboRFP-shAhr TRIPZ lentiviral vector 
(Open Biosystems, Huntsville, AL) was used to make viral transduction particles. 
Hs578T cells were transduced at an optimal MOI of 25 in medium containing 
hexadimethrine bromide (8 µg/mL polybrene; Sigma-Aldrich). Transduced cells 
were maintained in 1.5 µg/ml puromycin (Invitrogen, Grand Island, NY). Red 
fluorescent protein expression was maximal 48 hours after dox treatment (1.5 
µg/ml) of transduced cells.  
Transient transfection 
MCF10F cells (2 x 104 in 500 µL complete medium) were plated in a 24-
well plate, allowed to adhere overnight and co-transfected with the AHRE-driven 
firefly luciferase reporter construct pGudluc (1 µg/mL) (generously provided by 
Dr. M. Denison, UC, Davis) and CMV-green (0.5 µg/mL) using TransIT-2020 
transfection reagent (Mirus, Madison, WI). The medium was replaced after 24 
hours. Cells were left untreated or dosed with vehicle (DMSO, 0.1%) or 
CH223191 (10 µM) and harvested after 24 hours in Glo Lysis Buffer (Promega, 
San Luis Obispo, CA). Luciferase activity was determined with the Bright-Glo 
Luciferase System according to the manufacturer’s instructions (Promega). 
Luminescence and fluorescence were determined using a Synergy2 multifunction 
plate reader (Bio-Tek, Winooski, VT). shTdo2-expressing Hs578T cells were 
transiently transfected with pGudLuc and CMV-green 24 hours after plating and 
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luminescence was determined 24 hours later, as described above.  
For transient siRNA-mediatedTdo2 knockdown, Hs578T cells were 
transfected with 5 nM of each of two Tdo2-directed siRNA duplex constructs (5’-
GCAGCGAAGAAGACAAAUCACAAAC-3’ and  
5’-CCACUUAAUGUAAUCACUAUCUCAT-3’) or 10 nM scrambled siRNA duplex  
(5’-CGUUAAUCGCGUAUAAUACGCGUAT-3’). Fresh medium was added 24 
hours later. Cells then were transfected with pGudluc and CMV-green as above 
and luminescence determined 24 hours later.  
Scratch-Wound Assay 
Confluent monolayers of SUM149 cells were pre-treated in 6-well plates 
with vehicle (0.1% DMSO), 10–100 µM XA, 50–100 µM KYN, 0.5 µM FICZ, 1 µM 
B[a]P, or 1 nM TCDD with or without 10 µM CH223191, serum-starved for 24 
hours, scratched with a p200 pipette tip, and non-adherent cells were removed 
with PBS. Photographs were taken at the same location relative to the scratch at 
time 0 and every day thereafter for 3–4 days. The media was changed and cells 
were re-dosed daily. TScratch software (Tobias Gebäck and Martin Schulz, ETH 
Zürich) was used to quantify the closure of the scratch over time. None of these 
treatments affected cell viability or cell proliferation rates as determined by MTT 
assays. 
Gene Expression Preprocessing  
Fifty eight breast cancer cell lines from the Cancer Cell Line Encyclopedia 
(CCLE) containing Affymetrix U133 Plus 2.0-based transcriptomic information 
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(Barretina et al. 2012) were used to assess correlations between Ahr and 
Cyp1b1 expression. These data were normalized using Robust Multi-Array 
Average (Irizarry et al. 2003) using the R/Bioconductor (Team 2012)  package 
‘affy’, with raw probe levels mapped to Ensembl gene identifiers based on the 
custom Brainarray chip definition files (CDF) (Dai et al. 2005). Similarly, 
transcriptomic information from 977 primary mammary epithelial tumor samples 
and adjacent “normal” tissue from The Cancer Genome Atlas (Cancer Genome 
Atlas 2012) were used. The TCGA portal provides level 3, FPKM-normalized 
count data, which were used to determine relative Tdo2 mRNA levels and to 
analyze correlations between Ahr and Cyp1b1 within primary tissues. TCGA 
provides immunohistochemistry data on estrogen, progesterone and Her2 
receptor status, as well as tissue sample status (tumor vs. adjacent “normal” 
tissue) and tumor stage data, which were used to stratify the data based on ER, 
Progesterone and Her2 receptor status or on staging. All Pearson correlations, 
false discovery rate (FDR) corrections and plots were performed using the 
statistical programming language R.  
For Tdo2 expression analyses, TCGA data were retrieved from level three 
RNASeq version 2. Transcript abundance was estimated by RSEM (B. Li and 
Dewey 2011). RSEM estimated values were normalized using sample specific 
scaling factors (75% percentile) and multiplied by 1000. An added pseudo-count 
of one was used to compare log2-normalized expression of Tdo2 in tumor versus 
tumor-adjacent normal samples. The p values for Tdo2 expression comparisons 
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were calculated using Welch's unequal variances t-test in R. 
Immunohistochemistry 
Immunohistochemistry was performed on slides of paraffin-embedded, 5 
μm-thick sections of breast invasive ductal carcinoma in a tissue microarray (US 
Biomax, Inc., Rockville, MD) by standard protocol on an intelliPATH Automated 
Slide Staining System from Biocare Medical (Concord, CA). Briefly, the slides 
were heated for 15 minutes at 60 °C followed by deparaffinization starting with 
xylene and rehydrated through graded alcohols to distilled water. Antigen-
retrieval was then performed using Diva Decloaker (Biocare Medical) reagent at 
100 °C for 35 minutes, and then at 85 °C for 10 minutes. Slides were incubated 
with Biocare Medical Peroxidase 1 solution for 10 minutes at room temperature, 
washed with TBST, blocked with Biocare Medical Background Sniper for 30 
minutes and washed. Primary TDO-specific antibody (clone NBP2-13424, 1:100 
dilution, Novus Biologicals, Littleton, CO) was diluted in Biocare Medical Da Vinci 
Green Diluent and incubated for 2 hours at room temperature followed by 
washing in TBST. Incubation in Biocare Medical Mach 4 Universal HRP Polymer 
was then performed for 30 minutes followed by washing in TBST. DAB was 
diluted in DAB substrate buffer and applied to slides for 5 minutes followed by 
washing in deionized-H2O. A light hematoxylin stain was applied, the slides were 
dehydrated, air dried, and mounted, using EcoMount and a coverslip. 
Photomicrographs were taken with a Nikon Eclipse microscope connected to a Q 
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Capture Olympus camera and using NIS Elements software. Rabbit IgG was 
used as control to detect background non-specific staining. 
Statistical analyses 
 Unless otherwise indicated (see above), analyses of significance were 
performed using the Students T-test (GraphPad) with p values of <0.05 
considered significant. Data are expressed as means + standard errors.  
 
 
AIM ONE RESULTS 
AIM 1: Endogenous AHR ligand(s) responsible for AHR-dependent human 
mammary epithelial cell migration. 
Aim 1.1. Quantify levels of endogenous AHR ligands in ER-/PR-/Her2- 
malignant mammary epithelial cell lines.     
Aim 1.1.A. Tryptophan metabolites in the KYN and IS pathways induce AHR 
activity in nonmalignant mammary epithelial cells.   
It has been reported that at least three kynurenine pathway metabolites, 
kynurenine (KYN), xanthurenic acid (XA), and kynurenic acid (KA), are either 
AHR ligands or precursors to AHR ligands in human glial cells and hepatocytes 
(DiNatale et al. 2010; Opitz et al. 2011).  In the following studies, AHR activity 
was measured using pGudLuc 6.1, a luciferase-based reporter plasmid, which 
contains a 482 base pair DRE, upstream from the mouse Cyp1a1 gene start site 
(Rushing and Denison 2002).  We show that KYN, XA, KA and IS induce AHR 
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activity in a pGudLuc AHR reporter assay in non-malignant immortalized 
MCF10F and MCF10A cells, which have low baseline AHR activity, in a dose-
dependent manner. KYN and XA induce AHR activity in MCF10F cells with EC50s 
of 7.02 µM and 127 µM and maximal fold induction of 2.6 and 3.7, respectively 
(Figure 3 A and B; Parks, PhD). Similarly, KA and IS induce AHR activity in 
MCF10F and MCF10A cells respectively, with EC50s 180 µM and 1.08*103 µM 
and maximal fold induction of 1.8, and 5.6 respectively (Figure 3, C and D). 
Induction of pGudLuc activity was significantly inhibited by an AHR - specific 
antagonist, CH223191, demonstrating that the reporter assay induction was 
AHR-dependent (Figure 3). Importantly, KYN induced significant AHR activity at 
1–5 µM concentrations and produced a maximal increase in pGudLuc reporter 
activity at 50 µM (p<0.01), a concentration within the range of the previously 
reported KYN concentrations in human tumors and sera of cancer patients (Lyon 
et al. 2011; Opitz et al. 2011). Furthermore, XA induced significant AHR reporter 
activity at a concentration as low as 1 µM (p<0.05). KA induced significant AHR 
activity, but only at higher concentrations, i.e. > 100 µM (p<0.05). IS, which is a 
uremic toxin, significantly induced AHR activity at 10–200 µM, concentrations 
which falls in the range found in sera of kidney disease patients (Namba et al. 
2010; Brettschneider et al. 2013). These results support the hypothesis that 
tryptophan metabolites KYN, XA, KA and IS can induce AHR activity in 
mammary epithelial cells, with KYN, XA, and IS demonstrating the highest 
potency and efficacy.  
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Aim 1.1.B. Hs578T cells produce physiologically relevant levels of 
kynurenine and xanthurenic acid, two endogenous AHR ligands. 
Given the ability of KYN, XA and IS to induce AHR activity in 
nonmalingnant mammary epithelial cell lines, it was predicted that one or more 
ER- malignant mammary epithelial cell lines produces these metabolites. Since 
KYN and its metabolites can be produced by mammalian cells from tryptophan 
and are likely to accumulate in the media, as they do in the tumor 
microenvironment (Opitz et al. 2011; J. Y. Chen et al. 2014), a rapid colorimetric 
method for measuring KYN in supernatants (Hara et al. 2008; Lee et al. 2014) 
was used to quantify the accumulation of KYN in culture supernatants of a panel 
of ER-PR-/Her2- mammary eptithelial cell lines over the course of 48 hours. The 
rapid colorimetric kynurenine assay is summarized in Figure 4. In this assay, the 
aromatic amino group of KYN present in the medium reacts with  
p-dimethylaminobenzaldehyde (Ehrlich reagent), forming a product that absorbs 
at λ max 480 nm, in proportion to the KYN concentration (Hara et al. 2008). 
Absorbance measurments were normalized for background by subtracting 
absorbance observed in unconditioned medium from each supernatant 
measurment. Two-day supernatants from two ER-/PR-/Her2- cells lines, Hs578T 
and MDA-MB-231, had significantly greater change in KYN concentration, as 
compared to MCF10F (Figure 5). These results suggest that two of the screened 
panel of cell lines, namely Hs578T and MDA-MB-231, produce and excrete KYN, 
with the highest accumulation after 48 hours observed in Hs578T.  
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 KYN accumulation in cell supernatant may depend on two factors: time 
and the abundance of tryptophan. For example, different tryptophan 
concentrations are reported for conventional media base used for SUM149, 
Hs578T and MDA-MB-231 cells (4, 9, and 16 mg/L, respectively, Table 2).  Low 
tryptophan substrate concentration in SUM149 media may have contributed to 
the low KYN signal observed in SUM149, but not Hs578T or MDA-231 cells 
where more tryptophan is available from the media for kynurenine synthesis. 
Alternatively, different rates of KYN accumulation may have affected results seen 
at the 48 hour time point (Figure 5). To determine the dependence of KYN 
accumulation on time, supernatant was collected from Hs578T, SUM149 and 
MDA-MB231 cells at 0 – 92 hours. The rapid colorimetric KYN assay 
demonstrated a gradual KYN accumulation in Hs578T  (Figure 6 A, empty 
circles) and MDA-MB231 (Figure 6 C, empty circles) conditioned medium, but not 
in SUM149-conditioned medium (Figure 6 B, empty circles). When SUM149 
media was supplemented with enough tryptophan to approach concentration 
reported for MD-MB-231 medium, KYN accumulation was still not observed, 
indicating that lack of SUM149 KYN production is not due to low tryptophan 
concentration (Figure 6 B, crosses). However, supplementation of Hs578T cell 
media resulted in greater accumulation of KYN (maximum 3.6-fold vs. 2.2-fold), 
indicating that exess tryptophan concentration may affect KYN accumulation in 
cells that are able to produce it (Figure 6 A, crosses). Collectively, colorimetry 
findings are consistent with the presence of KYN in Hs578T and MDA-MB-231 
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cells.  
To determine the concentrations of AHR ligands from the kynurenine and 
indole branches in cell extracts and supernatants, targeted LC/MS analysis using 
triple quadrupole mass spectrometer was performed. Triple quadrupole mass 
spectrometry allows identification and quantification of compounds based on the 
differences in ion trajectories resulting from mass to charge ratios (m/z), unique 
to each compound and its fragmented ions (Figure 7). Table 3 lists the 
parameters used for the present purpose. Figure 8 A shows representative 
chromatograms used to determine sample metabolite concentrations.  
To determine the potential contribution of medium and serum to 
intracellular metabolite concentration, LC/MS analysis was used to test 1) 
metabolite levels in fresh medium (supplemented with bovine serum, 10% 
vol/vol), 2) four-day cell supernatants and 3) bovine serum used to supplement 
Hs578T medium. Given the colorimetric results showing KYN-related absorbance 
in the two-day Hs578T conditioned medium, it was hypothesized that the cells 
produce and secrete one or more metabolites into the supernatant, leading to 
increased KYN, and potentially XA and KA concentrations in four-day cell 
supernatant, as compared to fresh medium. Since IS production requires a 
bacteria-derived tryptophanase that is not present in mammalian cells (Figure 2), 
it was expected that the source of IS found in cell lysates is supplemented serum 
in the medium. It was therefore anticipated that IS would be detected in the fresh 
medium and that no significant accumulation of IS would be observed in cell 
  
55 
supernatant after a four day period.  
LC/MS analysis of the serum, Hs578T cell supernatant or fresh medium 
did not detect XA or KA (Figure 8 B). However, a KYN concentration of 150 µM 
was detected in four-day Hs578T-conditioned supernatant (Figure 8 B). KYN was 
detected at a concentration of 28 µM in bovine serum used to supplement 
Hs578T cell medium (10% vol/vol), indicating that part of the KYN in fresh 
medium comes from the serum. IS was detected at the highest concentration in 
the serum (9.7 µM), followed by cell culture supernatant and fresh medium 
containing 10% serum (2.7 µM and 0.73 µM respectively), suggesting that bovine 
serum is the source of IS in the medium and the cells.  
It was next hypothesized that Hs578T cell lysates contain one or more of 
the three kynurenine branch metabolites at concentrations sufficient to activate 
the AHR.  Previously, our group identified IS in media of MCF10F cells using 
non-targeted metabolomics profiling, with the likely source being the 
supplemented serum (unpublished data), raising the possibility that IS may also 
be present in Hs578T cells and medium. Indeed, all four metabolites were 
detected in Hs578T cell lysates. Intracellular metabolite concentrations, 
calculated from the number of cells harvested, cell lysate concentrations, and 
approximate cell volume, were determined to be 90.3 µM for KYN, 4.5 µM for XA, 
0.52 µM for KA and 1.92 µM for IS (Figure 8 C). Both the KYN and XA 
concentrations were sufficient to induce a significant ~1.5–2.5-fold increase in 
AHR reporter activity in mammary epithelial cell lines (Figure 3 B and C).  
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Notably, the Hs578T intracellular KYN concentration (90.3 µM) was 22 times 
higher than concentration in fresh medium (6.8 µM).  This finding is consistent 
with the increased absorbance over time in Hs578T cell supernatant found with 
the colorimetric KYN assay (Figure 6) and indicates that KYN accumulates in 
Hs578T cell supernatant over time. 
Aim 1.2. Determine the functional activities of identified tryptophan 
metabolites and compare them to environmental AHR ligands. 
Aim 1.2.A. Endogenous AHR ligands KYN and XA accelerate migration of 
SUM149 cells.   
 It has been suggested that the AHR plays a role in cell migration and 
metastasis (Brooks and Eltom 2011; G. D. Goode et al. 2013; G. Goode et al. 
2014). Therefore, it would be predicted that tryptophan metabolites of the KYN 
pathway, which increase AHR activity, would accelerate cancer cell migration. 
SUM149 cells, which do not produce kynurenine (Figures 5 and 6), were used to 
test this prediction. To directly determine if the more abundant kynurenine 
pathway metabolites, KYN, XA, or the indole metabolite IS, accelerate tumor cell 
migration, SUM149 cells were grown to confluence, monolayers scratched, and 
cultures treated with titered doses of KYN, XA, IS or metabolite plus AHR 
inhibitor. Wound closure was then quantified 36 (for KYN and XA) or 48 hours 
(for IS) later. Treatment with 50–100 µM XA or KYN alone significantly 
accelerated cell migration (Figure 9 A and 9 B). Addition of 10 µM CH223191 to 
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XA or KYN - treated cultures significantly decreased cell migration (p<0.001), 
demonstrating AHR dependence. Individual KYN and XA concentrations used 
were either less than (KYN) or approach (XA) the concentrations of each 
metabolite present in the tumor cells (Figure 9 B). Interestingly, while 10 µM XA 
did not significantly affect migration (Figure 9 B) and 50 µM KYN increased 
migration by 51% (p<0.05) (Figure 9 B), a combination of 10 µM XA and 50 µM 
KYN significantly accelerated cell migration by 87% (Figure 9 B) (p<0.00001). 
This migration rate after treatment with both XA and KYN was significantly 
greater than treatment with either 10 µM XA or 50 µM KYN alone (p<0.001 and 
p<0.05 respectively).  This increase in cell migration was dramatically inhibited by 
CH223191 (Figure 9, B). These data suggest that the presence of two (or more) 
AHR ligands, as is likely within the tumor environment, induces a more profound, 
AHR-dependent biologic effect than either metabolite alone. Treatment with 50 or 
100 µM of IS significantly increased migration by 89 and 86% respectively, and 
this increase was inhibited by CH223191 (Figure 9, C and D). 
 Collectively, these results demonstrate that AHR-dependent cell migration 
is induced in cells by tryptophan metabolites formed from KYN and IS pathways 
of tryptophan metabolism. Tryptophan metabolites formed from KYN pathway 
induce cell migration at concentrations within the range found in tumor cells. IS 
induces cell migration at concentrations within the range found in patients with 
kidney disease and mice with breast cancer drug-induced nephrotoxicity (Zgoda-
Pols et al. 2011).  
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Aim 1.2.B. IS induces ALDH1 activity in SUM149 cells. 
 IS is a known uremic toxin that accumulates in serum in association with 
kidney damage (Schroeder et al. 2010). It therefore may accumulate in sera of 
patients undergoing TNBC treatments, since some of these treatments are 
nephrotoxic (Hartmann et al. 2000; Petrelli et al. 2014).  Given the association 
between AHR activity and cancer stem cell characteristics, including increased 
ALDH1 activity that is linked to chemotherapeutic resistance (Nishikawa et al. 
2013; Stanford et al. 2016) and cancer relapse (Raha et al. 2014), it was 
hypothesized that IS will induce ALDH activity in TNBC cell line SUM149. Five-
day treatment with 100 µM IS significantly induced ALDH1 activity, measured by 
ALDEFLOURTM staining, in SUM149 cells (Figure 10).  This effect was reversed 
with the addition of AHR inhibitor CH223191 (Figure 10 B). These results 
demonstrate that IS may induce cancer stem cell markers associated with cancer 
relapse and chemo resistance at concentrations within the range that is 
associated with kidney damage. 
Aim 1.2.C. Environmental AHR ligands accelerate migration of 
SUM149 cells.  
The ability of endogenous AHR ligands to accelerate cell migration 
suggests the possibility that environmental AHR ligands, some of which have 
been associated with breast cancer incidence (Revich et al. 2001; Warner et al. 
2002; Brody et al. 2007; Warner et al. 2011; Manuwald et al. 2012), similarly 
affect tumor cell migration. To test this prediction, SUM149 cells were grown to 
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confluence, cell monolayers scratched, and cultures treated with: 1) 0.5 µM 6-
formylindolo[3,2-b]carbazole (FICZ), a tryptophan photo-metabolite and high 
affinity AHR ligand, 2) 1 µM benzo[a]pyrene (B[a]P), a prototypic PAH and 
carcinogenic environmental AHR ligand (Russo et al. 1993), of which exposure is 
correlated with breast cancer incidence (D. Li et al. 1999), or 3) 1 nM 2,3,7,8-
tetrachlorodibenzo[p]dioxin (TCDD), a persistent, high affinity environmental AHR 
ligand, exposure to which is associated with an increased incidence of breast 
cancer (McGregor DB1 1998). FICZ, B[a]P and TCDD significantly accelerated 
wound closure (50%, p<0.05, 86%, p<0.001 and 67%, p<0.01 respectively) 
(Figure 11). These results demonstrate that different classes of environmental 
AHR ligands have the capacity to mimic endogenous AHR ligands in their ability 
to increase cell migration in this model.  
AIM ONE DISCUSSION 
While several endogenous molecules either activate the AHR or give rise 
to metabolites that activate the AHR (DiNatale et al. 2010), evidence for their 
contribution to specific biological outcomes has only begun to be generated 
(DiNatale et al. 2010; Opitz et al. 2011). To investigate tryptophan metabolites as 
potential endogenous AHR ligands in breast cancer, our lab screened a panel of 
tryptophan metabolites in an AHR-dependent reporter assay. Our results led to 
the present focus on the kynurenine and indoxyl sulfate branches of tryptophan 
metabolism.  Here we show that tryptophan metabolites of these two branches 
induce cell migration and, in case of IS, ALDH1 activity at physiologically relevant 
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doses. 
Kynurenine pathway metabolites represent promising candidates as 
contributors to breast cancer through AHR activation, given the association 
between breast cancer and aberrant tryptophan metabolism (DeGeorge and 
Brown 1970; E. M. Bell et al. 1971; Davis et al. 1973; Fahl et al. 1974; E. D. Bell 
et al. 1975; Lehrer et al. 1988; Y. Chen et al. 2009; Girgin et al. 2009; Tang et al. 
2014) and accumulation of KYN in patient sera (Lyon et al. 2011). To date, no 
studies have directly evaluated levels of these potential mediators of tumor 
biology within malignant breast cells, and this is the first time intracellular 
concentrations of KYN or production of XA or KA by breast cancer cells has been 
evaluated. Notably, KYN levels within tumor cells (93 µM) and in tumor cell 
supernatants (150 µM), as quantified here, and KYN levels in breast cancer 
patient sera characterized elsewhere (2.3 + 1.1 µM) (Lyon et al. 2011) approach 
(patient serum levels) or exceed (intracellular concentrations) those shown to be 
capable of activating the AHR in mammary epithelial cells (Figure 3) and driving 
cell migration (Figure 9). This is in contrast to a previous study in which only 1 
µM KYN, a dose insufficient to activate the AHR (Figure 3), was detected in 
breast cancer cell supernatants. Moreover, in order to parallel a physiological 
environment, our migration assay included a combination treatment of KYN and 
XA (50 μM and 10 μM respectively) within the range detected in Hs578T cells 
(140 μM and 5 μM respectively). The mechanism responsible for more 
accelerated migration after treatment with the combination of metabolites, 
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compared to either treatment alone, requires further investigation. One possible 
explanation is that XA and KYN affect each other’s uptake by the cell, leading to 
more efficient uptake when present in combination. Studies show that AHR 
transcriptionally regulates several families of anion transporters (Cheng et al. 
2005; Maher et al. 2005), including OAT transporters involved in KYN and XA 
uptake (Wikoff et al. 2011), raising the possibility that these tryptophan 
metabolites may affect transporter expression via AHR activation. 
Our analysis demonstrates that the most likely source of another AHR 
ligand, IS, in the cells and cell medium is the bovine serum used to supplement 
the medium. These results are consistent with the lack, in mammalian cells, of 
the bacterial enzyme tryptophanase required for tryptophan metabolism to IS. 
However, an AHR-dependent increase in tumor cell migration (Figure 9) and 
activity of a cancer stem cell marker ALDH1 (Figure 10) were observed with an 
IS dose that falls within the range of serum levels that accumulate in animals with 
platinum based drug-induced kidney damage (Zgoda-Pols et al. 2011; T. Liu et 
al. 2012) and in patients with acute kidney injury (AKI) (Wu et al. 2013). IS - 
mediated induction of migration and ALDH1 activity is consistent with our 
previous findings that AHR drives migration and induces cancer stem cell 
characteristics (Stanford et al. 2016). Given that ALHD1 activity is associated 
with chemo-resistance and associated with poor prognosis (Tomita et al. 2016), 
while cell migration is required for invasion, elevated serum IS resulting from 
breast cancer chemotherapy-induced nephrotoxicity (Hartmann et al. 2000; Farry 
  
62 
et al. 2012; Lotan et al. 2012) could contribute to poor outcome and cancer 
relapse by activating the AHR (Figure 12). This is particularly important for 
TNBC, for which nephrotoxic platinum-based drug therapy is being considered 
(Figure 12) (von Minckwitz and Martin 2012). Our findings therefore warrant 
careful consideration of chemotherapy-associated nephrotoxicity in the context of 
its effect on breast cancer progression. Of note, given that KYN, which induces 
cell migration by activating the AHR, is also a uremic toxin (Sallee et al. 2014), 
cancer exacerbation may occur in patients treated with nephrotoxic platinum 
based drugs due to accumulation of not just IS, but multiple AHR-activating 
nephrotoxic tryptophan metabolites.  
One important implication of results presented here is the suggestion that 
environmental AHR ligands mimic endogenous ligands and enhance tumor cell 
migration (Figure 11). Both TCDD, a poorly metabolized and persistent AHR 
ligand, and B[a]P, a readily metabolized ligand, accelerated migration in vitro, as 
did FICZ, a purported endogenous AHR ligand not detected by LC/MS in either 
our tumor cells or culture medium (data not shown).  While previous studies 
report reduced migration after exogenous ligand-mediated AHR activation, the 
exact effect of AHR activation on different measurements of malignant phenotype 
likely depends on the context. For example, cancer cells change morphology and 
rely on changing sets of migratory mechanisms at earlier vs. later stages of 
invasive phenotype (Thiery 2002), as well as in response to changes in 
microenvironment (Friedl and Wolf 2003).  Results presented here demonstrate 
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that common environmental AHR ligands may exacerbate cancer progression via 
non-genotoxic mechanisms involving AHR activation.  
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AIM ONE FIGURES 
Aim 1, Figure 3: KYN, XA, KA and IS induce AHR activity in nonmalignant 
mammary epithelial cells 
For titrations with KYN, XA and KA MCF10F cells were transfected with 
pGudLuc and CMV-green control reporter plasmids and left untreated or treated 
with vehicle or 0.1 – 400 µM kynurenine, xanthurenic acid or kynurenic acid with 
or without 10 mM of the AHR-specific antagonist, CH223191. The CMV-green-
normalized RLU value in each experimental group was normalized to CMV-
green-normalized RLU values from untreated cells. Data from 3–5 experiments 
are presented as means + standard errors. The titration curve with IS was 
prepared in the same way as described above, using MCF10A cells. Asterisks 
indicate significant increases in AHR activity compared to vehicle-treated groups, 
*p<0.05, **p<0.01, ***p<0.001. Superscript crosses (+) indicate significant 
decreases in AHR activity following AHR antagonist treatment, +p<0.05 , 
++p<0.01, +++p<0.0001. Note: KA and XA titrations were performed by Ashley 
Parks, PhD. 
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Aim 1, Figure 3 
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Aim 1, Figure 4: Kynurenine colorimetric assay 
The rapid kynurenine assay involves treatment of the sample with trichloroacetic 
acid (TCA) in order to hydrolyse L-formyl kynurenine to kynurenine, followed by a 
reaction with Erlich’s reagent to form a product that absorbs at λ 480 nM. The 
outcome of this assay therefore reflects a combination of L-formyl kynurenine 
and kynurenine concentrations in the original sample.   
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Aim 1, Figure 4 
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Aim 1, Figure 5: KYN is elevated in supernatants of Hs578T and MDA-MB-
231 cells. 
Malignant and non-malignant mammary epithelial cell lines were grown in 
6-well plates and fed with 1 ml per well of medium. Supernatants were then 
collected from separate wells at 48 hours. Collected supernatants were treated 
with 30% (v/v) trichloroacetic acid and 4-p-dimethylaminobenzaldehyde in glacial 
acetic acid and assayed for kynurenine accumulation using the colorimetric 
method described in the Methods section. Results shown represent fold-change 
in concentration from time point zero are presented as means + standard errors 
from 3 independent experiments. Asterisks indicate significant increase in 
absorbance difference between unconditioned medium and 48 hour conditioned 
medium compared to MCF10F cells.  *p<0.05. 
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Aim 1, Figure 5 
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Aim 1, Table 2. Tryptophan concentrations in mammary epithelial cell 
media. 
The table shows documented tryptophan concentrations in media bases used to 
grow Hs578T, SUM149 and MDA-MB-231 cells. 
 
  
  
71 
 
Cell line Medium base Tryptophan  
Concentration (mg/L) 
Hs578T DMEM/F12 9 
SUM149 DMEM/K12 4 
MDA-MB-231 DMEM/1X 16 
 
Aim 1, Table 2 
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Aim1, Figure 6: KYN accumulates over time in supernatant of Hs578T and 
MDA-MB-231, but not SUM149 cells. 
A) Hs578T, B) SUM149 and C) MDA-MB-231 cells were grown in 6-well plates 
and fed with 1 ml per well of medium. Hs578T and SUM149 cell media were 
supplemented with vehicle or 30 or 60 uM tryptophan, respectively, so as to 
approach equal tryptophan concentrations between media used for the three cell 
lines. MDA-MB-231 cells were treated with vehicle. Supernatants were then 
collected from separate wells at time points 55 h, 72 h and 92 h. Media not 
exposed to cells was used as 0 h time point. Kynurenine accumulation was 
measured, as described in Figure 2. For the Hs578T cells, arrow points to the 
concentration detected in 4-day Hs578T supernatant by LC/MS (150 µM). 
Results shown represent fold-change in concentration from time point zero, and 
are presented as means + standard errors from 3 independent experiments.  
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Aim 1, Figure 6.  
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Aim 1, Figure 7: Detection and quantification of metabolites using triple 
quadrupole LC/MS analyzer 
General schematic of triple quadrupole analyser. Injected sample is fist ionized. 
Q1 selects ions of pre-set m/z mass allowing them to pass into the collision 
quadrupole, where ions are further fragmented.  Q3 selects for ions of pre-set 
m/z mass allowing them to pass to a detector. Results are recorded as counts 
per second vs. time (minutes) 
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Aim 1, Figure 7 
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Aim 1, Table 3. Parameters used for metabolite detection and quantification 
by LC/MS. 
For targeted metabolomics analysis of tryptophan metabolites, commercially 
obtained metabolites were first injected into the analyzer. Collected results 
indicate the mode and m/z ratio of fragments specific to each metabolite. These 
ratios were then used to set the mode and m/z selection for Q1 and Q3 
guadrupoles for analyzing experimental samples.  
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Metabolite Mode Q1 Q3 
Kynurenine - 207.018	 143.892	
Kynurenic Acid - 187.915	 143.783	
Xanthurenic Acid - 206.05	 160.02	
Indoxyl Sulfate + 211.7	 79.899	
 
Aim 1, Table 3 
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Aim1, Figure 8: Tryptophan metabolites in the kynurenine pathway are 
detected in Hs578T cell lysates and supernatants. 
A) Representative chromatograms showing kynurenine (KYN), xanthurenic acid 
(XA) and kynurenic acid (KA) peaks detected by LC/MS in blanks, positive 
metabolite controls, and Hs578T lysates. Positive controls (solutions of 
commercially obtained metabolites) were used to identify peaks in test samples 
(indicated by arrows). The area under each peak is linearly dependent on 
metabolite concentration. Titered concentrations of each metabolite were used to 
create standard curves for calculating sample metabolite concentrations. B) 
Metabolite concentrations (µM) in fresh media (supplemented with 10% bovine 
serum), pure bovine serum and four-day Hs578T cell supernatant were 
determined as described in “A”.  C) Intracellular metabolite concentrations (µM) 
were determined from sample metabolite concentrations obtained as described 
in “A”, the number of cells used to produce cell lysates, and the approximate 
mammalian epithelial cell volume of 2,0003 μm. 
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Aim 1, Figure 8 
  
  
80 
B       
 
C 
 
Aim 1, Figure 8.  
  
XA KA KY
N IS
0
10
20
30
40
160
 Su
pe
rn
ata
nt
 co
nc
en
tra
tio
n (
µ
M
)
serum
supernatant
medium 150
KY
N XA KA IS
0
5
10
120
In
tra
ce
llu
la
r C
on
ce
nt
ra
tio
n 
 (µ
M
)
93.3
  
81 
Aim 1, Figure 9: KYN, XA and IS accelerate migration of SUM149 cells. 
Confluent layers of SUM149 cells were scratched and treated with vehicle 
or the indicated doses of kynurenine (KYN) or xanthruenic acid (XA) or a 
combination of KYN and XA with or without CH223191. A) and C) 
Representative photos from one of 5–17 experiments (for KYN and XA 
treatments) and 3–9 experiments (for IS treatments) are presented. Black lines 
indicate borders of the original scratch wound. B) and D) For experiments 
described in “A” and “C”, the percent exposed area at 36 hours (for KYN and XA 
treatment) and 48 hours (for IS treatment), relative to the exposed area at time 0, 
was quantified using TScratchTM imaging software. Data are presented as means 
+ standard errors. Asterisks indicate a significant decrease in exposed area (i.e., 
increased migration) compared to vehicle-treated cells or between groups 
indicated by brackets, *p<0.05, ***p<0.001. Superscript crosses (+) indicate a 
significant increase in exposed area (slowing of migration) after addition of 
metabolite(s) with 10 µM CH223191, +++p<0.001.  
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Aim 1, Figure 10: IS treatment increases ALDH1 activity in SUM149 cells. 
A). SUM149 cells were treated every 24 hours, for 5 days, with vehicle or 100 µM 
IS, with or without AHR inhibitor, 10 µM CH223191.  Cells were harvested and 
stained with ALDEFLUOR in the presence or absence of 
diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. ALDH activity, , 
measured as fluorescent substrate production, was quantified by flow cytometry. 
Regions representing ALDHhigh cells were selected using Aldeflour + DEAB 
samples as negative controls.  B). SUM149 cells were treated as in “B” and 
assayed for the percentage of ALDHhigh cells. Data from six separate 
experiments is presented as mean fold-change compared to naïve + standard 
error. Asterisks indicate a significant decrease in the percentage of ALDHhigh cells 
compared to vehicle treatment. *p<0.05. A cross indicates a significant increase 
in ALDHhigh cells compared the equivalent treatment without CH223191. +p<0.05 
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Aim 1, Figure 11: Environmental AHR ligands accelerate migration of 
SUM149 cells. 
A) Confluent layers of SUM149 cells were scratched and treated with 
vehicle, 0.5 µM FICZ, 1 µM B[a]P, or 1 nM TCDD as described in the Methods 
section, and photographed at time 0 and at 36 hours. Black lines indicate the 
borders of the original scratch wound. Presented are representative images from 
one of 4 (FICZ) or 5 (B[a]P, TCDD) independent experiments. B) For the 
experiments described in “A”, the percent exposed area at 36 hours was 
quantified using TScratchTM imaging software. Data are presented as the mean 
exposed area, normalized to time 0 + standard errors. Asterisks indicate a 
significant decrease in exposed area (i.e., increased migration) compared to 
vehicle-treated cells, *p<0.05, **p<0.01, ***p<0.001.   
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Aim 1, Figure 12: Proposed mechanism for the role of IS in cancer 
progression after nephrotoxic chemotherapy in TNBC 
TNBC chemotherapy with nephrotoxic drugs, such as platinum-based 
chemotherapeutics, may result in acute kidney injury (AKI) and subsequent 
elevation of serum indoxyl sulfate (IS). High serum IS may in turn exacerbate 
cancer progression and worsen prognoses by inducing AHR in tumor cells. 
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AIM TWO RESULTS 
Aim 2: Define the contributions of key enzymes in the KYN pathway to cell 
malignancy via endogenous AHR ligand production and assess the effects AHR 
activity on these metabolic pathways. 
Aim 2.1. Determine the contribution of key enzymes in the tryptophan 
catabolism pathway to AHR activity and cell migration.  
Aim 2.1.A. TDO expression in breast cancer cell lines. 
Despite elevated AHR expression and activity in many breast cancers, 
and the potential for the AHR to play a significant role in mediating breast cancer 
invasion and/or migration, at least in ER- cells (Brooks and Eltom 2011; G. D. 
Goode et al. 2013; J. Y. Chen et al. 2014; G. Goode et al. 2014; Z. D. Li et al. 
2014; Parks et al. 2014), the exact nature of and mechanisms responsible for 
production of endogenous AHR ligands that drive AHR activity in breast cancer 
have not been established. In Aim 1 it was shown that malignant mammary 
epithelial cells contain, produce and secrete into the medium KYN and its 
downstream metabolite XA at concentrations capable of activating the AHR and 
driving AHR-dependent cell migration. Therefore, it was hypothesized that 
proximal, rate-limiting enzymes in the kynurenine pathway, TDO and/or IDO1/2, 
regulate AHR signaling and TNBC functionality by facilitating endogenous AHR 
ligand production.  
To determine which, if any, of these enzymes are expressed in human 
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mammary epithelial cell lines, Tdo2 and Ido1 and Ido2 mRNA levels were 
quantified by RT-qPCR in a non-malignant mammary epithelial cell line 
(MCF10F), four TNBC cell lines (BP1, Hs578T, MDA-MB-231, and MDA-MB-231-
BO), and one inflammatory breast cancer cell line (SUM149). Only one cell line, 
MDA-MB-231, produced detectable levels of Ido1 mRNA (after 30 cycles) and no 
lines contained detectable Ido2 mRNA (not shown). Little to no Tdo2 was 
detected in MCF10F, BP1, SUM149 and MDA-MB-231-BO cells (Figure 13 A). 
MDA-MB-231 expressed low but significantly (p<0.01) higher Tdo2 levels than 
MCF10F cells. In contrast, Hs578T cells expressed 46-fold more Tdo2 than 
MCF10F cells. TDO protein levels roughly correlated with Tdo2 mRNA 
expression in these cell lines, with Hs578T cells exhibiting approximately 57-fold 
more TDO protein than MCF10F cells (Figure 13 B and C).   
Aim 2.1.B. Tdo2 expression in primary breast tumors.  
Analysis of the TCGA database revealed that primary breast cancers 
express dramatically elevated levels of Tdo2 mRNA as compared with adjacent, 
“histologically normal” tissue (“AN”) regardless of estrogen, progesterone or Her2 
receptor status (Figure 2 A, p<0.001). TNBC tumors express significantly higher 
Tdo2 than ER+ tumors (Figure 2 A, p<0.001). Interestingly, normal tissue 
adjacent to TNBC tumors, which are known to be more aggressive, expresses 
modestly higher Tdo2 levels than the corresponding adjacent normal tissue from 
ER+ tumors (Figure 14 A) (p<0.05). When samples were segregated according to 
tumor staging, it can be seen that tumors at stages 1–3 express significantly 
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higher Tdo2 than adjacent normal tissue (Figure 14 B). Tdo2 expression in Stage 
4 tumors is also higher than in adjacent normal tissue, although sample size of 
adjacent normal tissue (2 samples) precluded statistical analysis (Figure 14 B). 
Furthermore, stage 4 breast cancers express significantly higher Tdo2 mRNA 
than stage 3 tumors (p<0.05), again suggesting that the highest Tdo2 levels 
characterize the most aggressive cancers.  
Aim 2.1.C. TDO contributes to endogenous AHR activity in tumor cells. 
Previous studies demonstrate that the AHR is “constitutively active” in 
several different types of cancers (C. Y. Chang and Puga 1998; Trombino et al. 
2000; Roblin et al. 2004; Currier et al. 2005; X. Yang et al. 2005; J. T. Chang et 
al. 2007; X. Yang et al. 2008; Barhoover et al. 2010; Korzeniewski et al. 2010; 
DiNatale et al. 2011) and that it may play a role in tumor invasion and/or 
migration (Diry et al. 2006; Schlezinger et al. 2006; Gramatzki et al. 2009; 
Dietrich and Kaina 2010; Brooks and Eltom 2011; G. D. Goode et al. 2013). In 
TNBC cell lines, this high baseline AHR activity enforces expression of a 
prototypic AHR target gene, Cyp1b1 (X. Yang et al. 2008). A significant positive 
correlation between Ahr and Cyp1b1 levels in 58 mammary epithelial cancer cell 
lines annotated in the Cancer Cell Line Encyclopedia (CCLE) dataset (FDR = 3.8 
x 10-7) and in 977 mammary tumors represented in the TCGA dataset (FDR < 2.2 
x 10-16) (Figure 15) suggests that the AHR is constitutively active in human breast 
cancers in general, presumably because of the presence of endogenous ligands, 
and that Cyp1b1 expression is a useful surrogate marker for AHR expression 
  
93 
and/or activity.  
To determine if TDO influences AHR activity, presumably through 
production of endogenous ligands, Tdo2 was down-regulated by stable 
transduction of Hs578T cells with Tdo2-specific shRNA (shTdo2) or by transient 
transfection with Tdo2-specific siRNA. Tdo2 levels were quantified by RT-qPCR 
to confirm knockdown. Cyp1b1 levels were quantified as a surrogate marker for 
endogenous gene-specific AHR activity (X. Yang et al. 2008) and pGudLuc 
reporter activity was assayed as a more general measure of AHR activity. Stable 
expression of shTdo2 significantly reduced Tdo2 levels by 83% (p<0.05), 
endogenous Cyp1b1 levels by 31% (p<0.01), and pGudLuc activity by 37% 
(p<0.05) (Figure 16 A, B and C). Similarly, transient transfection with Tdo2-
specific siRNA significantly reduced Tdo2 levels by 49% (p<0.001), Cyp1b1 
expression by 24% (p<0.05), and pGudLuc activity by 17% (p<0.01) (Figure 16 
D, E and F). These data indicate that TDO is at least partially responsible for 
baseline (constitutive) AHR activity in Hs578T tumor cells.  
Given that TDO contributes to AHR activity in Hs578T cells, it was 
predicted that TDO over-expression would increase AHR activity. Inflammatory 
breast cancer-derived SUM149 cells, which do not express detectable levels of 
Tdo2 or Ido1/2, were used to test this prediction. Indeed, ectopic Tdo2 
expression in SUM149 cells significantly increased pGudLuc activity (Figure 17). 
These data demonstrate that TDO contributes to AHR activity in tumor cells. 
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Aim 2.1.D. TDO contributes to endogenous AHR ligand production in tumor 
cells. 
Given the high levels of TDO in Hs578T (Figure 13), and accumulation of 
KYN detected by colorimetric and LC/MS analysis in (Figures 5, 6 and 8), it was 
predicted that TDO is at least partially responsible for KYN accumulation in 
Hs578T cells. As expected, down-regulation of Tdo2 by stable transduction with 
Tdo2-specific shRNA significantly (p<0.01) inhibited KYN accumulation in 
supernatants (Figure 18 A). Conversely, expression of Tdo2 plasmid in SUM149 
cells resulted in increased KYN accumulation in supernatants (Figure 18 B). It 
was therefore concluded that TDO significantly contributes to production of 
tryptophan-derived endogenous AHR ligands.  
Aim 2.1.E. TDO activity contributes to tumor cell migration. 
Previous reports indicate that the AHR plays a role in cell migration and 
metastasis (Brooks and Eltom 2011; G. D. Goode et al. 2013; G. Goode et al. 
2014). Since Tdo2 expression in SUM149 cells increased accumulation of an 
endogenous AHR ligand KYN in culture supernatants (Figure 18 B), and 
increased pGudLuc activity (Figure 17), while direct treatment of SUM149 cells 
with KYN and XA increased cell migration (Figure 9), it was predicted that TDO 
over-expression would lead to production of endogenous AHR ligands, thereby 
accelerating cancer cell migration. Indeed, ectopic Tdo2 expression in SUM149 
cells increased the rate of wound healing (Figure 19 A and B). In all cases, 
migration was slowed by addition of AHR inhibitor CH223191 (Figure 19 B). 
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These data demonstrate that TDO activity contributes to cell migration in an AHR-
dependent manner. 
Aim 2.2. Define the effects of AHR activity on the tryptophan catabolism 
pathway. 
Aim 2.2.A. AHR regulates TDO expression in Hs578T cells. 
The AHR can control Ido1 expression in non-malignant, murine dendritic 
cells (Vogel et al. 2008; Nguyen et al. 2010). To determine if the AHR regulates 
Tdo2 in human malignant mammary cells, AHR expression or activity was down-
regulated in Hs578T cells, which express relatively high TDO levels (Figure 13), 
with a doxycycline-inducible Ahr-specific shRNA or AHR inhibitor CH223191. 
Indeed, both Ahr knockdown and AHR inhibition significantly reduced Tdo2 
expression (p<0.05) (Figure 20 A and B). To test whether AHR-mediated up 
regulation of Tdo2 expression can be generalized to other cell lines, two 
additional mammary epithelial cell lines were used:  ER-/Pro-/Her2- malignant 
mammary epithelial cell line BP1, and an ER-/Pro-/Her2+ malignant mammary 
epithelial cell line HCC202. Induction of Ahr-specific Dox-inducible shRNA in BP1 
and treatment of HCC202 cells with CH223191, down-regulated Tdo2 expression 
(Figure 20 C and D). These results demonstrate that AHR activity plays a 
significant role in maintaining Tdo2 expression in mammary epithelial tumor cells 
in what appears to be a positive feedback loop that mediates a relatively high 
level of tumor cell migration.  
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AIM TWO DISCUSSION 
Aim 1 results demonstrate that malignant mammary epithelial Hs578T 
cells produce three metabolites via the kynurenine branch at concentrations 
capable of inducing AHR and driving cell migration. Aim 2 investigates the 
mechanisms via which these metabolites are produced.  
The rate-limiting step in the kynurenine branch of tryptophan metabolism 
is catabolized by TDO or IDO1/2, both of which have been found to be elevated 
in breast cancer (DeGeorge and Brown 1970; E. M. Bell et al. 1971; Davis et al. 
1973; E. D. Bell et al. 1975; Lehrer et al. 1988; Cascino et al. 1991). While 
IDO1/2 can be expressed in multiple tissues under healthy conditions, normal 
TDO expression is restricted to liver and glial cells.  We found that among a 
panel of triple negative non-malignant and malignant mammary epithelial cell 
lines, TDO is highly expressed in malignant triple negative cell line Hs578T 
(Figure 13) where KYN, and its product XA are present at concentrations 
capable of activating the AHR and inducing cell migration, as was shown in Aim 
1. Ido mRNA was not detected in Hs578T cells or in four of the other five lines 
tested. As expected, TDO knockdown significantly reduced production and 
accumulation of KYN (Figure 18), confirming that TDO activity represents a rate-
limiting step in baseline production of these AHR ligands.  
We report elevated Tdo2 in primary tumor samples compared to adjacent 
normal counterparts, independently of receptor status or stage (Figure 14), and 
significantly elevated Tdo2 in the most aggressive Stage 4 tumors, compared to 
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less aggressive stages (Figure 14 B).  These results are indicative of an 
important role for TDO in breast cancer progression.  A greater up-regulation of 
Tdo2 in TNBC, compared to ER+ cells (Figure 14 A) suggests that this highly 
aggressive TNBC may be more dependent on TDO expression than ER+ 
cancer. Collectively, our results suggest that TDO may be as or more important 
to breast cancer biology than IDO, although significantly more is known of IDO 
expression in other cell types (Mellor and Munn 2004; Braun et al. 2005; Hwang 
et al. 2005; Choe et al. 2014; Staudacher et al. 2015; Yeung et al. 2015).   
AHR inhibitors CH223191 and CB7993113 slow cell migration in the 
scratch wound assay (Parks et al. 2014)(Figure 9). These and other data 
(Barouki et al. 2007; DiNatale et al. 2012; G. D. Goode et al. 2013; Lahoti et al. 
2014) are consistent with the hypothesis that AHR activity drives cell migration, a 
required step in the progression to a more aggressive phenotype (van Zijl et al. 
2011). Since AHR activity is influenced by TDO-dependent endogenous AHR 
ligands, it was predicted that TDO expression would correlate with AHR activity 
and the rate of cell migration.  We show here that when over-expressed in breast 
cancer cells, TDO contributes to AHR activity (Figure 16 and Figure 17), 
kynurenine production (Figure 18) and, in an AHR-dependent process, cell 
migration (Figure 19).  
Finally, we show for the first time, that AHR knockdown with shRNA or 
suppression of AHR activity with CH223191 significantly reduces Tdo2 mRNA 
expression in two different ER-/PR-/Her2- breast cancer cell lines and in one 
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Her2+ line (Figure 20). This result is reminiscent of the influence of the AHR on 
Ido expression in antigen-presenting cells (Nguyen et al. 2010) and uniquely 
demonstrates a complete, positive feedback loop within breast cancer cells. 
Interestingly, no AHR binding sites could be found in the promoter region of 
TDO.  This means that AHR may be regulating Tdo2 expression indirectly, or via 
other AHR signaling pathways. Possible alternative pathways may involve AHR 
dimerization with a partner other than ARNT and binding to non-consensus DNA 
response elements on the TDO promoter. For example, AHR interacts with the 
glucocorticoid receptor (GR), modulating GR response gene expression (Sato et 
al. 2013).  On the other hand, Tdo2 expression has been shown to be regulated 
by glucocorticoids (Ott et al. 2015). Therefore AHR-GR crosstalk is a potential 
noncanonical way of AHR-mediated Tdo2 regulation. Future studies may 
investigate the potential involvement of GR, KLF6, NF-kB and other alternative 
AHR partners that act with the AHR to regulate genes via nonconsensus DNA 
sequences. 
The AHR-TDO loop model supported by the results of this project is 
summarized in Figure 21.  The AHR-TDO loop may be initiated and sustained 
by AHR ligands produced within a given malignant cell, by adjacent malignant 
cells, and/or by non-malignant cells of the surrounding tumor microenvironment. 
In that vein, KYN accumulates in the tumor microenvironment (Puccetti et al. 
2015) where it can act in a “paracrine” manner in breast (J. Y. Chen et al. 2014) 
and other cancers (Opitz et al. 2011). Importantly, recent work in our lab showed 
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that primary human tumors highly express TDO and that this TDO expression is 
detected in both the malignant cells and in the fibroblasts that reside in the 
stroma surrounding malignant tissue (Figure 22).  This result is supportive of the 
important role that TDO has in mammary epithelial cell and is consistent with an 
autocrine/paracrine communication between the tumor and its microenvironment 
via production of tryptophan-derived AHR ligands. This autocrine/paracrine 
communication network may represent a novel route through which malignant 
cells and cells of the tumor microenvironment perpetuate tumor aggressiveness.   
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AIM TWO FIGURES 
Aim 2, Figure 13: TDO mRNA and protein expression in breast cancer cell 
lines. 
A) Cell lines were grown to 70% confluency and analyzed by RT-qPCR for 
Tdo2 mRNA expression. Gene expression levels were normalized to 18S RNA 
levels and the fold-difference relative to the non-malignant mammary epithelial 
cell line MCF10F was calculated using ΔΔCt values and the Pfaffl method. A 
low but consistent signal was detected in MCF10F cells at an average of 31 
cycles. Data are presented as means + standard errors from 3 experiments. 
Asterisks indicate a significant difference relative to Tdo2 expression in 
MCF10F cells, **p<0.01. B) A representative western immunoblot (4 
experiments total) of TDO and, as a control, β-actin protein expression in 
mammary epithelial cell lines. An additional file shows the whole western blot in 
more detail (see Additional File 1) C) Band densities were determined from TDO 
western immunoblots and normalized to β-actin band densities. Data are 
presented as means + standard errors from 4 experiments. Asterisks indicate a 
significant increase in β-actin-normalized TDO expression relative to expression 
in MCF10F cells, *p<0.01 **p<0.01. 
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Aim 2, Figure 14: Tdo2 expression is elevated in primary breast tumors. 
Tdo2 expression data for primary breast tumors (T) and paired tumor 
adjacent histologically normal tissue (AN) were acquired from the cancer genome 
atlas (TCGA) and plotted with respect to: A) estrogen (ER), progesterone (PR) 
and Her2 receptor status and B) tumor stage (Note: the “AN, Stage 4” group 
contains only 2 samples, precluding statistical analyses).  Each box plots 
indicates the sample median and surrounding first and third quartiles. Whiskers 
indicate interquartile range.  Asterisks indicate significant differences, *p<0.05, 
***p<0.001.  
  
103 
 
 
Aim 2, Figure 14 
 AN    T            
Lo
g 2
 N
or
m
al
iz
ed
  
m
R
N
A 
E
xp
re
ss
io
n 
ER+ Triple Negative  PR+Her2+ 
 AN      T            
12.5 
10 
7.5 
5 
2.5 
0 
AN      T            AN       T            
12.5 
10 
7.5 
5 
2.5 
0 
Stage 1 Stage 2 Stage 3 Stage 4 
Lo
g 2
 N
or
m
al
iz
ed
  
m
R
N
A 
E
xp
re
ss
io
n 
A
B 
AN    T            AN    T              AN    T            
n=78 n=782 n=21 n=126 n=13 n=153 
n=19 n=181 n=65 n=591 n=25 n=241 n=2 n=21 
  
104 
Aim 2, Figure 15: Positive correlation between Ahr and Cyp1b1 mRNA 
expression in breast cancer cell lines and primary breast cancers. 
Presented are linear regression analyses of Ahr and Cyp1b1 expression 
using data from: A) Fifty-eight breast cancer cell lines in the Cancer Cell Line 
Encyclopedia (CCLE) database and B) 977 primary breast cancers in The 
Cancer Genome Atlas (TCGA). Pearson moment correlation coefficients (r) and 
false discovery rates (FDR) are reported for each correlation. Grey-filled circles 
represent ER- negative cell lines (A) and primary cancers (B).  
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Aim 2, Figure 15 
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Aim 2, Figure 16: Tdo2 knockdown reduces AHR activity in Hs578T cells. 
Hs578T cells were stably transduced with scrambled control shRNA or 
Tdo2-specific shRNA (A-C) or transiently transfected with scrambled or Tdo2-
specific siRNA (D-F). Cells were assayed by RT-qPCR for Tdo2 (A, D) or 
Cyp1b1 (B, E). Gene expression levels were normalized to 18S RNA and fold-
differences were calculated relative to non-transfected cells using the Pfaffl 
method. In “C” and “F”, cells also were transfected with the AHR-driven pGudLuc 
reporter plasmid and, for normalization for transfection efficiency, with CMV-
green plasmid and assayed 24 hours later for luciferase activity and green 
fluorescence. Data are presented as the means + standard errors from 4–10 
experiments. Asterisks indicate significant decreases in normalized gene 
expression or pGudLuc activity,  *p<0.05, ***p<0.001.   
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Aim 2, Figure 16 
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Aim2, Figure 17: Ectopic Tdo2 expression induces AHR activity in SUM149 
cells. 
Control plasmid and Tdo2-transduced SUM149 cells were transfected with 
the AHR-driven pGudLuc reporter plasmid and, for normalization for transfection 
efficiency, with CMV-green plasmid and assayed 48 hours later for luciferase 
activity and green fluorescence. Data are presented as means + standard errors 
from 4 independent experiments. An asterisk indicates a significant increase in 
AHR activity, p<0.05. 
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Aim 2, Figure 17 
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Aim 2, Figure 18: TDO expression is responsible for KYN accumulation in 
tumor cell supernatants. 
A). Hs578T cells were stably transduced with scrambled control shRNA or 
Tdo2-specific shRNA and Tdo2 knockdown was confirmed as described in 
Figure 4A. Supernatants were collected at time 0, 22, 55 and 92 hours and 
assayed for kynurenine concentration as described in Figure 5. Data are 
presented as means + standard errors from 3 independent experiments. 
Asterisks indicate a significant reduction in kynurenine relative to levels in cells 
transfected with control shRNA. *p<0.5 **p<0.01. C). Control plasmid and Tdo2-
transduced SUM149 cells were plated in 6-well plates, allowed to adhere 
overnight, and fed with 1 ml per well of fresh medium at time 0. Supernatants 
were collected at time 0 and at 48 hours and assayed for kynurenine production 
as described in Figure 5.  Data are presented as time 0 -normalized means + 
standard errors from 4 independent experiments. An asterisk indicates a 
significant increase in kynurenine relative to levels in cells transduced with 
control plasmid. *p<0.05.   
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Aim 2, Figure 18  
0 20 40 60 80 100
0
1
2
3
4
5
Hours
Ky
nu
re
ni
ne
 c
on
ce
nt
ra
tio
n
 (F
ol
d 
C
ha
ng
e 
Fr
om
 T
im
e 
0) Hs578T
* **
Control shRNA
shTDO
co
ntr
ol
Td
o2
0.0
0.5
1.0
1.5
Ky
nu
re
ni
ne
 C
on
ce
nt
ra
tio
n 
(F
ol
d 
In
cr
ea
se
 F
ro
m
 T
im
e 
0)
*
A B 
  
112 
Aim 2, Figure 19: Ectopic TDO expression accelerates tumor cell migration. 
A) SUM149 cells were stably transduced with control plasmid or Tdo2 
plasmid. TDO over-expression was confirmed via qPCR and Western blot 
analysis (data not shown). Confluent layers of control plasmid or Tdo2-
transduced SUM149 cells were scratched and left untreated or treated with 
vehicle or the AHR antagonist CH223191. Representative photos taken at 48 
hours from one of 7 experiments are presented. Black lines indicate borders of 
the original scratch wound. B) For the 7 experiments described in “A”, the 
percent exposed area at 48 hours, relative to the percent exposed area at time 0, 
was quantified using TScratchTM imaging software. Data are presented as means 
+ standard errors. Asterisks indicate significant differences in the time 0 - 
normalized percent exposed area from the respective control plasmid-transfected 
groups (no brackets) or between the groups indicated by the brackets , *p<0.05, 
**p<0.01  
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Aim 2, Figure 20: AHR regulates Tdo2 expression in Hs578T cells. 
A) Hs578T cells stably transduced with doxycycline (DOX)-inducible Ahr-
specific shRNA, were cultured with or without 1.5 µg/ml DOX for 5 days and 
Tdo2 levels quantified by RT-qPCR. Tdo2 expression was normalized to 18S 
RNA and the fold difference relative to Tdo2 levels in non-transfected cells was 
calculated using the Pfaffl method. Data from 4 experiments are presented as 
means + standard errors. An asterisk indicates a significant reduction in Tdo2 
levels, *p<0.05. B) Hs578T cells were treated with vehicle or 10 µM CH223191 
for 5 days and Tdo2 expression quantified by RT-qPCR as described in “A”. Data 
from 4 experiments are presented as means + standard error. An asterisk 
indicates significant reduction in Tdo2 levels, *p<0.05. C) BP1 cells stably 
transduced with doxycycline (DOX)-inducible Ahr-specific shRNA, were cultured 
with or without 1.5 µg/ml DOX for 5 days and Tdo2 levels quantified by RT-
qPCR, as described in “A”. Data from 4 experiments are presented as means + 
standard error. An asterisk indicates significant reduction in Tdo2 levels, *p<0.05. 
D) HCC202 cells were treated with vehicle or 10 µM CH223191 for 5 days and 
Tdo2 expression quantified by RT-qPCR as described in “A”. Data from 2 
experiments are presented as means + standard error. 
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Aim 2, Figure 21: Model for an endogenous or environmental AHR ligand-
driven, TDO-dependent, positive feedback loop in breast cancer. 
In triple negative breast cancer cells, TDO, the most proximal and rate-
limiting enzyme in the kynurenine pathway of tryptophan metabolism, generates 
kynurenine (KYN) which is further metabolized by kynurenine aminotransferase 
(KAT) to xanthurenic acid (XA) (potentially as well as other downstream AHR 
ligands, including kynurenic acid/KA). These endogenous AHR ligands 
constitutively enforce AHR transcriptional activity, driving breast cancer cell 
migration. In a positive feedback loop, the AHR also up-regulates Tdo2 
expression. Environmental AHR ligands may initiate and/or exacerbate this 
positive feedback loop by initiating or enhancing AHR activity. 
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Aim 2, Figure 22: TDO expression in primary breast tumor and surrounding 
stroma. 
 TDO staining is brown. Right arrow points to malignant mammary 
epithelial tissue expressing TDO. Left arrow points to TDO-positive fibroblast in 
the stroma surrounding malignant mammary epithelial tissue.  (E. Landesman, 
PhD) 
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                    Landesman, PhD 
Aim 2, Figure 22 
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CONCLUSION AND FUTURE DIRECTIONS 
Data presented in this project demonstrate that two distinct tryptophan 
metabolism branches, the kynurenine branch and the microbiome - dependent 
IS synthesis branch are sources of endogenous AHR ligands capable of 
inducing cancer migration and cancer stem cell characteristics. Two 
mechanisms are proposed for how these two branches affect breast cancer via 
the AHR (Figure 12 and Figure 21).  
First, IS - mediated AHR induction and cancer progression, at levels 
within the range found in sera upon kidney injury, warrants further attention to 
cancer-promoting effects of platinum drug-associated nephrotoxicity, which may 
result in high serum IS levels, in TNBC patients. Studies that correlate IS levels 
in TNBC patients given nephrotoxic chemotherapy with disease outcomes would 
shed further light on this issue. If the presented model is true, control of 
nephrotoxicity-associated serum IS levels in TNBC patients with chelating 
agents or by IS synthesis inhibition may be one way to improve patient 
outcomes after platinum-based chemotherapy. In addition, these findings would 
underline the need for development of more targeted and less toxic treatments 
for TNBC. On a broader scale, given the role of AHR in many types of cancer, 
our findings warrant particular attention to the possible effects of kidney injury in 
general on long-term cancer outcomes.  
Second, we propose that TDO-over-expressing breast cancer migration 
is at least partially driven by AHR activity that is dependent on endogenous AHR 
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ligands. This conclusion is supported by: 1) reduced Hs578T cell migration after 
TDO knockdown and 2) increased migration of SUM149 cells after treatment 
with physiological doses of KYN, XA, or a combination of the two, or after over-
expression of TDO.  
Additionally, our findings present two potential mechanisms for how 
environmental AHR ligands can exacerbate breast cancer. Exogenous AHR 
ligands may interfere or exacerbate this feed forward loop by: 1) supporting 
AHR–mediated cell migration, and 2) supporting AHR-regulated endogenous 
ligand synthesis. Therefore we have identified a feed-forward loop in ER- breast 
cancer cells in which AHR activity contributes to production of its own 
endogenous ligands KYN and XA, which in turn drive cell migration.  
While there are targeted therapies for receptor positive breast cancers, 
triple negative breast cancers are heterogeneous and possibly need to be 
characterized for targeted therapeutics. Given that KYN accumulates in sera of 
breast cancer patients, identification of ER- cancers benefiting from TDO/IDO-
AHR loop may be one method for such characterization. Given that the TCGA 
database showed increased TDO expression in ER- breast cancers, compared 
to all others, and this result was confirmed by our own findings (Figure 22), the 
AHR-TDO relationship could play a particularly important role in triple negative 
cancers.   Since IDO1 is also over-expressed by many breast cancers (J. T. Liu 
et al. 2011), and its expression can be regulated by the AHR (Vogel et al. 2008), 
the feed-forward mechanism identified by our study could be contributing to 
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breast cancer regardless of the whether IDO or TDO is responsible for KYN 
production.  Indeed, preliminary data in our lab showed in MDA-MB-231 
mammary epithelial cells, which express low levels of Ido1 (data not shown) and 
Tdo2 (Figure 13), CRISPR-mediated knockout of Ahr suppresses both Ido1 and 
Tdo2 expression (data not shown). These data are consistent with the existence 
in breast cancer of a feedback loop in which AHR drives production of its own 
endogenous ligands is via either Tdo2 or Ido1 or both.   
In breast cancers in which malignancy is exacerbated by AHR-TDO or 
AHR-IDO positive feedback loop, two main points in the loop can be targeted for 
therapeutic purposes: 1) production of endogenous AHR ligands and 2) the 
AHR activity. IDO and TDO inhibition has recently garnered a lot of interest due 
to the involvement of these enzymes in tumor immune evasion. Currently 
several TDO inhibitors are being studied as tumor chemotherapeutics (Pilotte et 
al. 2012), and IDO inhibitors are in being tested in breast cancer clinical trials for 
antagonizing tumor immunosuppression (Garber 2012). Findings presented here 
indicate that TDO and IDO inhibition can have value for cancer treatment that 
goes beyond immunomodulation. An attractive aspect of AHR-targeted 
therapeutics, on the other hand, is that they can be a universally applied for 
inhibition of the loop, regardless of whether one or both of the rate-limiting 
enzymes contribute to kynurenine pathway-derived AHR ligand production. In 
this vein, AHR inhibitors or modulators can be particularly useful for breast 
cancer treatment.   
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Several sAHRms are currently being studied as AHR-targeted 
therapeutics. These include I3C derivative 3,3'-Diindolylmethane (DIM), which is 
currently being tested in clinical trials to treat several types of solid tumors, 6-
methyl-1,3,-trichlorodibenzofuran (MCDF), which is specifically being studied as 
an ER- breast cancer therapeutic (Zhang et al. 2009).  In addition, several 
approved pharmaceuticals that are classified as AHR modulators have been 
shown to inhibit breast cancer progression in vitro and in vivo (S. Safe et al. 
2013).  Our lab has previously identified a novel AHR inhibitor CB7993113, 
which inhibited breast cancer cell line migration and invasion (Parks et al. 2014).  
Additional in vivo experiments showed that CB7993113 inhibits metastasis of 
bone-seeking MDA-MB231 cells in a cardiac-injection breast cancer metastasis 
model (data not shown), indicating that this chemical may present as a new 
class of therapeutically valuable AHR antagonists.   
In conclusion work presented here outlines several mechanisms for how 
cancer-exacerbating AHR activity can be sustained in breast cancer 
independently of environmental AHR ligands, and how environmental AHR 
ligands can initiate or exacerbate this process. Our model for the role of IS in 
cancer promotion after platinum-based chemotherapeutics presents a potential 
need to refine chemotherapy treatments, especially for patients with TNBC.  On 
the other hand, the identification of an AHR-TDO feedback loop in TNBC 
presents an opportunity for characterization of breast cancers that could be 
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susceptible to specific therapeutics targeting both the kynurenine pathway and 
AHR activity.   
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